C. Chapple

发表

Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis.

R. Dmochowski, P. Abrams, P. van Kerrebroeck, 2014, European urology.

The future of clinical practice guidelines in urology.

J. Wolf, P. Dahm, B. Konety, 2011, European urology.

Recent developments in technology for the assessment and management of incontinence

A. McCarthy, C. Chapple, C. Hillary, 2015, Journal of medical engineering & technology.

The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study

Andrea Tubaro, C. Thompson, K. Coyne, 2009, BJU international.

Modern evaluation of lower urinary tract symptoms in 2014

C. Chapple, A. Mangera, 2014, Current opinion in urology.

What was hot at the ICS meeting 2014?

B. Couri, N. Siddiqui, C. Chapple, 2015, Neurourology and urodynamics.

Conventional and ambulatory urodynamic findings in women with symptoms suggestive of bladder overactivity.

D. Rosario, C. Chapple, D J Rosario, 2001, The Journal of urology.

Definition of normality of pressure‐flow parameters based on observations in asymptomatic men

H. Woo, D. Rosario, C. Chapple, 2008, Neurourology and urodynamics.

Primer: questionnaires versus urodynamics in the evaluation of lower urinary tract dysfunction—one, both or none?

C. Chapple, 2005, Nature Clinical Practice Urology.

Assessment of Electrospun and Ultra-lightweight Polypropylene Meshes in the Sheep Model for Vaginal Surgery.

S. MacNeil, E. Mazza, J. Deprest, 2020, European urology focus.

Urological symptom clusters and health‐related quality‐of‐life: results from the Boston Area Community Health Survey

S. Tennstedt, A. Wein, R. Rosen, 2009, BJU international.

State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

M. Marberger, B. Djavan, C. Chapple, 2004, Urology.

A three month double‐blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction

T. Christmas, P. Abrams, R. Kirby, 1994 .

Prazosin in the treatment of prostatic obstruction. A placebo-controlled study.

R. Kirby, C. Chapple, E. Milroy, 1987, British journal of urology.

Endoscopic urethrotomy versus open urethroplasty for men with bulbar urethral stricture: the OPEN randomised trial cost-effectiveness analysis

A. Mundy, Jing Shen, J. McGrath, 2021, BMC Urology.

Cholinergic modulation of spontaneous contractions in the pig bladder: The role of the mucosa in the different bladder regions

K. Lawson, C. Chapple, N. McKay, 2011 .

Abnormal electromyographic activity of the urethral sphincter, voiding dysfunction, and polycystic ovaries: a new syndrome?

T. Christmas, C. Fowler, R. Kirby, 1988, BMJ.

The functional role of beta-adrenoceptor subtypes in mediating relaxation of pig urethral smooth muscle.

R. Chess-Williams, Ken‐ichiro Yoshida, C. Chapple, 2003, The Journal of urology.

The role of the urothelium in mediating bladder responses to isoprenaline

R. Chess-Williams, C. Chapple, H. Akino, 2007, BJU international.

The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.

Z. Gabriel, C. Chapple, V. Khullar, 2008, European urology.

Urinary Incontinence and Pelvic Prolapse

Christopher R. Chapple, C. Chapple, I. Milsom, 2012 .

Asymptomatic bladder neck incompetence in nulliparous females.

S. Blease, C. Chapple, E. Milroy, 1989, British journal of urology.

Botulinum toxin injection therapy in the management of lower urinary tract dysfunction

C. Chapple, A. K. Patel, C. Chapple, 2006, International journal of clinical practice. Supplement.

Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician

C. Chapple, 2004, BJU international.

Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS

K. Coyne, S. Kaplan, C. Chapple, 2009, BJU international.

The afferent system and its role in lower urinary tract dysfunction

D. Grundy, C. Chapple, D. Daly, 2011, Current opinion in urology.

How should bladder sensation be measured?: ICI‐RS 2011

C. Tannenbaum, G. V. van Koeveringe, J. Wyndaele, 2012, Neurourology and urodynamics.

Efficacy and safety of tolterodine extended‐release in men with overactive bladder symptoms treated with an α‐blocker: effect of baseline prostate‐specific antigen concentration

P. Abrams, S. Herschorn, C. Chapple, 2010, BJU international.

Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis

G. Jackson, G. Hackett, I. Eardley, 2013, International journal of clinical practice.

Towards a better understanding of involuntary detrusor activity

D. Rosario, C. Chapple, S. Radley, 2005, BJU international.

Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT.

C. Rice, S. Noble, P. Abrams, 2020, Health technology assessment.

Treatment decision‐making among men with lower urinary tract symptoms: A qualitative study of men's experiences with recommendations for patient‐centred practice

P. Abrams, C. Chapple, M. Drake, 2020, Neurourology and urodynamics.

25 Years of Experience with the AUA Symptom Index: Increasing Recognition that the Bladder is an Unreliable Witness.

C. Chapple, 2017, The Journal of urology.

Tamsulosin: an overview

C. Chapple, K. Andersson, 2002, World Journal of Urology.

Medical Therapy and Quality of Life

C. Chapple, 1998, European Urology.

Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade.

C. Chapple, 1998, British journal of urology.

Alpha 1-adrenoceptor subtypes in the human prostate.

C. Chapple, M. Wyllie, P. Greengrass, 1994, British journal of urology.

Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.

P. Abrams, J. Wyndaele, C. Chapple, 1996, European urology.

Landmarks in vaginal mesh development: polypropylene mesh for treatment of SUI and POP

S. MacNeil, N. Mangır, C. Chapple, 2019, Nature Reviews Urology.

Tissue‐engineered buccal mucosa for substitution urethroplasty

S. MacNeil, C. Chapple, S. Bhargava, 2004, BJU international.

Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary Incontinence.

S. MacNeil, F. Montorsi, F. Burkhard, 2017, European urology.

Use of a simple in vitro fatigue test to assess materials used in the surgical treatment of stress urinary incontinence and pelvic organ prolapse

S. MacNeil, J. Deprest, N. Mangır, 2018, Neurourology and urodynamics.

Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia

C. Chapple, E. Siddiqui, 2017, Expert review of clinical pharmacology.

Male LUTS/BPH made easy /

A. Tubaro, C. Chapple, 2014 .

Overactive bladder syndrome: Current pathophysiological concepts and therapeutic approaches

N. Osman, C. Chapple, 2013, Arab journal of urology.

The management of overactive bladder syndrome: a review of the European Association of Urology Guidelines

N. Osman, C. Chapple, 2013 .

Abstracts, Poster Session

A. Zlotta, O. Rampin, J. Sullivan, 1999, European Urology.

Robotic Surgery as Applied to Functional and Reconstructive Urology.

N. Osman, N. Mangır, C. Chapple, 2019, European urology focus.

The use of laser as a therapeutic modality as compared to TURP for the small prostate ≤ 40ml: a collaborative review.

G. Morgia, G. Russo, F. Esperto, 2019, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

Safety and efficacy of transurethral needle ablation of the prostate for symptomatic outlet obstruction.

H. Woo, D. Rosario, C. Chapple, 1997, British journal of urology.

Terminology report from the International Continence Society (ICS) Working Group on Underactive Bladder (UAB)

R. Dmochowski, A. Wein, G. V. van Koeveringe, 2018, Neurourology and urodynamics.

Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome

P. Abrams, L. Cardozo, C. Chapple, 2006 .

Anatomy of the lower urinary tract

Anand K. Patel, C. Chapple, 2008 .

Failure of Urinary Drainage: Lower Tract

C. Chapple, J. Patterson, 2007 .

A rational approach to benign prostatic hyperplasia evaluation: recent advances

C. Chapple, A. Canda, S. Bhargava, 2004, Current opinion in urology.

Pharmacodynamics of anticholinergic agents measured by ambulatory urodynamic monitoring: A study of methodology

D. Smith, D. Rosario, C. Chapple, 1999, Neurourology and urodynamics.

Nocturia: morbidity and management in adults

L. Cardozo, C. Kelleher, C. Chapple, 2005, International journal of clinical practice.

Retropubic Suspension Surgery for Incontinence in Women

C. Chapple, 2012 .

Intra‐bladder wall transplantation of bone marrow mesenchymal stem cells improved urinary bladder dysfunction following spinal cord injury☆

R. Rahbarghazi, H. Salehi-pourmehr, L. Roshangar, 2019, Life sciences.

Editorial comment regarding diagnostic value of International Prostate Symptom Score (IPSS) voiding‐to‐storage subscore ratio in male lower urinary tract symptoms

C. Chapple, C. Chapple, 2011, International journal of clinical practice.

Pharmacological characterization of A‐131701, a novel α1‐adrenoceptor antagonist selective for α1A‐ and α1D‐compared to α1B‐adrenoceptors

R. Chess-Williams, M. Williams, C. Chapple, 1998 .

engineered pelvic floor repair material The effect of ascorbic acid and fluid flow stimulation on the mechanical properties of a tissue

S. MacNeil, N. Osman, C. Chapple, 2014 .

The effect of ascorbic acid and fluid flow stimulation on the mechanical properties of a tissue engineered pelvic floor repair material

S. MacNeil, N. Osman, C. Chapple, 2014, Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine.

Re: Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement

C. Chapple, K. Sievert, 2013 .

Can incontinence be cured? A systematic review of cure rates

J. Kleijnen, S. Hagen, S. Deshpande, 2017, BMC Medicine.

A prospective patient-centred evaluation of urethroplasty for anterior urethral stricture using a validated patient-reported outcome measure.

A. Mundy, C. Chapple, N. Watkin, 2013, European urology.

Male Lower Urinary Tract Symptoms and Cardiovascular Events: A Systematic Review and Meta-analysis.

S. Serni, S. Kaplan, K. McVary, 2016, European urology.

Randomized controlled trials for benign prostatic obstruction: problems and pitfalls

C. Chapple, C. R. Chapple, 2000, BJU international.

Overactive bladder: Is there a link to the metabolic syndrome in men?

H. Kölbl, L. Cardozo, P. van Kerrebroeck, 2010, Neurourology and urodynamics.

Overactive Bladder and Continence Guidelines: implementation, inaction or frustration?

L. Cardozo, C. Kelleher, D. de Ridder, 2008, International journal of clinical practice.

Safety and tolerability of the β3‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trial

V. Nitti, S. Herschorn, P. Radziszewski, 2014, International journal of clinical practice.

The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials

S. Mujais, M. B. Blauwet, C. Chapple, 2015, Quality of Life Research.

Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.

G. Amarenco, P. Radziszewski, C. Chapple, 2013, European urology.

A phase II dose-ranging study of mirabegron in patients with overactive bladder

O. Yamaguchi, J. Wyndaele, C. Chapple, 2013, International Urogynecology Journal.

Pharmacological Treatment of Overactive Bladder

A. Wein, C. Chapple, 2012 .

The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro.

R. Chess-Williams, C. Chapple, T. Yamanishi, 2001, Journal of autonomic pharmacology.

Urethral injury

C. Chapple, 2000 .

Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study.

F. Montorsi, U. Wetterauer, M. Speakman, 2015, European urology.

Systematic review and metaanalysis of genetic association studies of urinary symptoms and prolapse in women

Phillip R. Bennett, P. Rajan, T. Palmer, 2015, American journal of obstetrics and gynecology.

Patient-perceived outcomes in the treatment of stress urinary incontinence: focus on urethral injection therapy

L. Brubaker, D. Robinson, C. Chapple, 2007, International Urogynecology Journal.

EAU guidelines on urinary incontinence.

P. Abrams, J. Thüroff, W. Artibani, 2011, European urology.

Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review

S. Kaplan, M. Oelke, C. Chapple, 2015, Current medical research and opinion.

Erectile and Ejaculatory Function Following Anterior Urethroplasty: A Systematic Review and Meta-analysis.

K. Pang, I. Eardley, N. Osman, 2022, European urology focus.

Chapter 27 – PATHOPHYSIOLOGY OF STRESS INCONTINENCE

C. Chapple, F. Manassero, 2008 .

Spontaneous regression of pulmonary metastases from renal adenocarcinoma before nephrectomy

J. Newman, C. Chapple, M. X. Gannon, 1987, The British journal of surgery.

Recent developments in the management of detrusor overactivity

R. Chess-Williams, C. Chapple, L. Templeman, 2003, Current opinion in urology.

Words of wisdom: Re: The challenges facing academic urology training programs: an impending crisis.

C. Chapple, K. Sievert, 2013, European urology.

Could Reduced Fluid Intake Cause the Placebo Effect Seen in Overactive Bladder Clinical Trials? Analysis of a Large Solifenacin Integrated Database.

L. Cardozo, S. Herschorn, C. Chapple, 2017, Urology.

Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.

C. Roehrborn, F. Montorsi, C. Stief, 2013, European urology.

The burden of urgency urinary incontinence on health and wellbeing

N. Osman, C. Chapple, C. R. Chapple, 2013, International journal of clinical practice.

Urolume Stents in the Management of Benign Prostatic Hyperplasia

C. Chapple, E. Milroy, J. Nordling, 2002 .

A multitrait, multimethod matrix approach for a consumer-grade wrist-worn watch measuring sleep duration and continuity

D. Bliwise, E. Roitmann, C. Chapple, 2020, Sleep.

A stepwise approach to the treatment of the enlarged prostrate

C. Chapple, A. Mangera, 2010, International journal of clinical practice.

Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial

C. Dubeau, C. Chapple, A. Viegas, 2007, Current medical research and opinion.

Updated systematic review and meta-analysis of the comparative data on colposuspensions, pubovaginal slings, and midurethral tapes in the surgical treatment of female stress urinary incontinence.

M. Barber, M. Creta, V. Ficarra, 2010, European urology.

Are slings now the gold standard treatment for the management of female urinary stress incontinence and if so which technique?

B. Bemelmans, C. Chapple, 2003, Current opinion in urology.

The Vaginal Approach After Failed Previous Surgery

C. Chapple, 2006 .

Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence

C. Tannenbaum, L. Cardozo, A. Wein, 2009, Current opinion in urology.

Principles of ureteric reconstruction

C. Chapple, J. C. Damian Png, 2000, Current opinion in urology.

Demonstration of improved tissue integration and angiogenesis with an elastic, estradiol releasing polyurethane material designed for use in pelvic floor repair

S. MacNeil, N. Mangır, C. Chapple, 2018, Neurourology and urodynamics.

Haemodynamic evidence for per-operative cardiac stress during transurethral prostatectomy. Preliminary communication.

C. Chapple, E. Milroy, S. Coppinger, 1991, British journal of urology.

A contemporary view on the use of slings and artificial urinary sphincters for the treatment of post‐prostatectomy incontinence in England

C. Chapple, 2020, BJU international.

Emerging Minimally Invasive Treatment Options for Male Lower Urinary Tract Symptoms.

C. Roehrborn, H. Woo, M. Elhilali, 2017, European urology.

Botulinum toxin therapy for the management of lower urinary tract symptoms – has this come of age?

C. Chapple, A. Mangera, 2012 .

Intraprostatic injection therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.

C. Chapple, 2011, European urology.

Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA).

P. Dasgupta, S. Madersbacher, A. Apostolidis, 2011, European urology.

Use of botulinum toxin in the treatment of lower urinary tract disorders. Current status.

C. Chapple, A. Mangera, 2010, Archivos espanoles de urologia.

The urgency of the problem and the problem of urgency in the overactive bladder

A. Wein, C. Chapple, 2005, BJU international.

The effects of tamsulosin, a high affinity antagonist at functional α1A‐ and α1D‐adrenoceptor subtypes

R. Chess-Williams, C. Chapple, K. Furukawa, 1997 .

The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes.

R. Chess-Williams, C. Chapple, K. Furukawa, 1997, British Journal of Pharmacology.

The role of M2‐muscarinic receptors in mediating contraction of the pig urinary bladder in vitro

R. Chess-Williams, C. Chapple, T. Yamanishi, 2000, British journal of pharmacology.

D. Grundy, C. Chapple, N. McKay, 2014, The Journal of physiology.

Bladder outlet obstruction and the overactive bladder

N. Osman, C. Chapple, 2015 .

Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH

T. Tammela, A. Eisenhardt, N. Osman, 2015, World Journal of Urology.

Non-Hormonal treatment of BPH/BOO

N. Osman, C. Chapple, A. Mangera, 2014, Indian journal of urology : IJU : journal of the Urological Society of India.

Introduction

S. Kaplan, C. Chapple, 2009 .

Lower urinary tract symptoms: new perspectives on prevalence, burden and comorbidities. Introduction.

S. Kaplan, C. Chapple, 2009, BJU international.

Medical management of lower urinary tract symptoms in men: current treatment and future approaches

Anand K. Patel, C. Chapple, A. Patel, 2008, Nature Clinical Practice Urology.

Alpha adrenoceptor antagonists in the year 2000: is there anything new?

C. Chapple, 2001, Current opinion in urology.

β3‐Adrenoceptors in urinary bladder

O. Yamaguchi, C. Chapple, 2007 .

α1A‐Adrenoceptor mediated contraction of rat prostatic vas deferens and the involvement of ryanodine stores and Ca2+ influx stimulated by diacylglycerol and PKC

C. Chapple, I. Marshall, R. P. Burt, 1998, British journal of pharmacology.

The role of capacitative Ca2+ influx in the αlB‐adrenoceptor‐mediated contraction to phenylephrine of the rat spleen

C. Chapple, R. P. Burt, I. Marshall, 1995, British journal of pharmacology.

Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction.

R. Chess-Williams, C. Chapple, L. Stevens, 2007, European urology.

Bladder function after radical hysterectomy for cervical cancer

L. Cardozo, P. van Kerrebroeck, C. Kelleher, 2015, Neurourology and urodynamics.

Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study.

V. Nitti, D. de Ridder, C. Chapple, 2016, The Journal of urology.

Editorial comment on: Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report.

C. Chapple, 2009, European urology.

Mirabegron 50 mg once‐daily for the treatment of symptoms of overactive bladder: An overview of efficacy and tolerability over 12 weeks and 1 year

S. Kaplan, M. B. Blauwet, C. Chapple, 2014, International journal of urology : official journal of the Japanese Urological Association.

Systematic review and evaluation of methods of assessing urinary incontinence.

K R Abrams, A J Sutton, C. Shaw, 2006, Health technology assessment.

Hyperparathyroidism after neck irradiation

T. Christmas, C. Chapple, E. Milroy, 1988, The British journal of surgery.

A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial

W. White, C. Gratzke, S. Herschorn, 2018, Blood pressure monitoring.

Nerve fibre proliferation in interstitial cystitis

T. Christmas, C. Chapple, J. Rode, 2005, Virchows Archiv A.

Signal Transduction Pathways Associated with α1-Adrenoceptor Subtypes in Cells and Tissues Including Human Prostate

C. Chapple, I. Marshall, R. P. Burt, 1999, European Urology.

Pathophysiological Changes in the Obstructed Bladder

C. Chapple, 1994 .

The Anatomy and Innervation of the Bladder

C. Chapple, 1994 .

Loss of sensory neuropeptides in the obstructed human bladder.

G. Burnstock, C. Chapple, P. Milner, 1992, British journal of urology.

The human prostate gland: a histochemical and immunohistochemical study of neuropeptides, serotonin, dopamine beta-hydroxylase and acetylcholinesterase in autonomic nerves and ganglia.

G. Burnstock, C. Chapple, R. Crowe, 1991, British journal of urology.

Patients with lower motor spinal cord lesion: a decrease of vasoactive intestinal polypeptide, calcitonin gene-related peptide and substance P, but not neuropeptide Y and somatostatin-immunoreactive nerves in the detrusor muscle of the bladder.

G. Burnstock, J. K. Light, C. Chapple, 1991, The Journal of urology.

Which drugs are best for overactive bladder? From patients’ expectations to physicians’ decisions

M. Oelke, C. Chapple, I. Milsom, 2020, International journal of clinical practice.

Cholinergic innervation and muscarinic receptors in the human prostate.

J. J. de la Rosette, M. Michel, C. Chapple, 2008, European urology.

Darifenacin: first M3 receptor antagonist for overactive bladder

C. Chapple, S. Chaplin, 2007 .

Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder

C. Chapple, 2004, Expert opinion on investigational drugs.

Muscarinic receptor subtypes and management of the overactive bladder.

R. Chess-Williams, C. Chapple, T. Yamanishi, 2002, Urology.

Tolterodine: Selectivity for the Urinary Bladder Over the Eye (as Measured by Visual Accommodation) in Healthy Volunteers

C. Chapple, L. Nilvebrant, 2002, Drugs in R&D.

M3 muscarinic receptors but not M2 mediate contraction of the porcine detrusor muscle in vitro.

R. Chess-Williams, C. Chapple, T. Yamanishi, 2000, Journal of autonomic pharmacology.

MUSCARINIC RECEPTOR ANTAGONISTS IN THE TREATMENT OF OVERACTIVE BLADDER

C. Chapple, 2000, Urology.

Haemodynamic evidence for cardiac stress during transurethral prostatectomy.

C. Chapple, J. M. Walker, E. Milroy, 1992, BMJ.

Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome.

P. Abrams, P. Radziszewski, C. Chapple, 2014, The Journal of urology.

Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.

C. Chapple, J. Nazir, A. Wagg, 2017, European urology.

Antimuscarinics, β-3 Agonists, and Phosphodiesterase Inhibitors in the Treatment of Male Lower Urinary Tract Symptoms: An Evolving Paradigm.

N. Osman, C. Chapple, A. Mangera, 2016, The Urologic clinics of North America.

Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome.

S. Ferrero, G. M. Rosa, V. Nitti, 2016, European urology.

Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.

S. Kaplan, J. Klecka, C. Chapple, 2013, European urology.

A prospective audit of the use of a prostate clinic.

D. Rosario, C. Chapple, P. Cutinha, 1996, British journal of urology.

Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).

P. Abrams, E. Mueller, C. Gratzke, 2018, European urology.

Cardiovascular Safety of the β3‐Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial

W. White, C. Gratzke, S. Herschorn, 2018, Journal of clinical pharmacology.

The Role of the Specialist

A. Wein, C. Chapple, 2012 .

Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six european countries: report of the TRIUMPH study.

M. Koopmanschap, F. Rutten, R. Berges, 2006, European urology.

Stress incontinence injection therapy: what is best for our patients?

R. Dmochowski, A. Wein, L. Brubaker, 2005, European urology.

OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity

D. Globe, M. Chancellor, C. Chapple, 2013, Neurology.

D. Grundy, C. Chapple, N. McKay, 2019 .

A 12‐Week Placebo‐controlled Double‐blind Study of Prazosin in the Treatment of Prostatic Obstruction due to Benign Prostatic Hyperplasia

T. Christmas, P. Abrams, C. Chapple, 1992 .

Complications related to use of mesh implants in surgical treatment of stress urinary incontinence and pelvic organ prolapse: infection or inflammation?

S. MacNeil, N. Mangır, C. Chapple, 2019, World Journal of Urology.

Is Pharmacotherapy a Satisfactory Alternative Treatment for Benign Prostatic Hyperplasia

C. Chapple, I. Marshall, 1994 .

Is Pharmacotherapy for Benign Prostatic Hyperplasia an Alternative

C. Chapple, 1992 .

OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium

D. Grundy, C. Chapple, N. McKay, 2013, BJU international.

Transurethral Implantation of Macroplastique® for the Treatment of Female Stress Urinary Incontinence Secondary to Urethral Sphincter Deficiency

I. Mitsogiannis, C. Chapple, S. Radley, 2001, European Urology.

Epidemiology of Underactive Bladder

N. Osman, C. Chapple, C. Hillary, 2017 .

Overview of the Evaluation of Lower Urinary Tract Dysfunction

C. Chapple, A. Mangera, 2011 .

α1L-adrenoceptors mediate contraction of human erectile tissue.

R. Chess-Williams, C. Chapple, D. Sellers, 2018, Journal of pharmacological sciences.

Repository α 1 L-adrenoceptors mediate contraction of human erectile tissue

R. Chess-Williams, C. Chapple, D. Sellers, 2018 .

Functional and radioligand binding characterization of the α1L-adrenoceptor subtype of the human vas deferens.

R. Chess-Williams, C. Chapple, D. Sellers, 2015, Autonomic & autacoid pharmacology.

Muscarinic receptor function, density and G-protein coupling in the overactive diabetic rat bladder.

R. Chess-Williams, C. Chapple, N. McKay, 2006, Autonomic & autacoid pharmacology.

The treatment of vesicovaginal fistulae.

H. Woo, D. Rosario, C. Chapple, 1996, European urology.

Developing Repair Materials for Stress Urinary Incontinence to Withstand Dynamic Distension

S. MacNeil, C. Chapple, S. Roman, 2016, PloS one.

A diagnostic conundrum: Is it a periurethral diverticulum/cyst or a bulking agent (Bulkamid)?

N. Osman, C. Chapple, O. Akinjise-Ferdinand, 2022, Neurourology and urodynamics.

Particulate Versus Non-Particulate Bulking Agents In The Treatment Of Stress Urinary Incontinence

R. Dmochowski, C. Chapple, 2019, Research and reports in urology.

RRU_A_220216 299..310

R. Dmochowski, C. Chapple, 2019 .

An open, multicentre study of NASHA/Dx Gel (Zuidex) for the treatment of stress urinary incontinence.

A. Sultan, C. Chapple, F. Haab, 2005, European urology.

DEVELOPING AN AUTOLOGOUS ENGINEERED CONNECTIVE TISSUE USING A BIODEGRADABLE SCAFFOLD FOR THE TREATMENT OF STRESS URINARY INCONTINENCE AND PELVIC ORGAN PROLAPSE

S. MacNeil, N. Osman, C. Chapple, 2012 .

Pelvic organ prolapse and overactive bladder

L. Cardozo, C. Kelleher, A. Tubaro, 2010, Neurourology and urodynamics.

Recent advances in pelvic floor repair

S. MacNeil, C. Chapple, E. Mironska, 2019, F1000Research.

Developing a tissue engineered repair material for treatment of stress urinary incontinence and pelvic organ prolapse—which cell source?

S. MacNeil, N. Osman, C. Chapple, 2014, Neurourology and urodynamics.

Neurophysiology of the striated urethral sphincter in multiple sclerosis.

C. Fowler, I. Eardley, R. Kirby, 1991, British journal of urology.

A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis.

R. Dmochowski, P. Abrams, S. Madersbacher, 2012, European urology.

Role of endogenous transforming growth factor β (TGFβ) 1 in prostatic stromal cells *

C. Chapple, C. Eaton, A. Bretland, 2001 .

Fowler's syndrome—a cause of unexplained urinary retention in young women?

N. Osman, C. Chapple, 2014, Nature Reviews Urology.

The Investigation of Benign Prostatic Hyperplasia

C. Chapple, J. Noble, 1994 .

Night‐time voids, level of bother and sleep characteristics in a non‐patient population of wearable devices users

D. Bliwise, E. Roitmann, C. Chapple, 2020, International journal of clinical practice.

What are the causes and consequences of bladder overdistension?: ICI‐RS 2011

P. Abrams, L. Cardozo, J. Gajewski, 2012, Neurourology and urodynamics.

The role of M2 muscarinic receptor subtypes in mediating contraction of the pig bladder base after cyclic adenosine monophosphate elevation and/or selective M3 inactivation.

R. Chess-Williams, C. Chapple, T. Yamanishi, 2002, The Journal of urology.

Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of “Overactive bladder”

C. Chapple, 2014, Neurourology and urodynamics.

Reply: Unravelling Fowler's syndrome—current pathophysiological concepts

N. Osman, C. Chapple, 2014, Nature Reviews Urology.

What was hot at the ICS meeting 2013?

N. Osman, C. Chapple, K. Tikkinen, 2014, Neurourology and urodynamics.

Update summarising the conclusions of the international consultation on male lower urinary tract symptoms

C. Chapple, A. Mangera, 2015 .

Recent Advances in treatment of urethral stricture disease in men

N. Mangır, C. Chapple, 2020, F1000Research.

Suprapubic catheterisation and bowel injury.

C. Chapple, S. Hampson, A. Parikh, 1992, British journal of urology.

The emerging role of intravesical botulinum toxin therapy in idiopathic detrusor overactivity

C. Chapple, A. K. Patel, J. Patterson, 2006, International journal of clinical practice. Supplement.

Nocturia: not just the elderly

C. Chapple, A. Mangera, 2010, International journal of clinical practice.

Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.

T. Tammela, F. Montorsi, M. Wirth, 2011, European urology.

Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long‐term follow‐up of a prospective study

C. Chapple, 1998 .

Medical, Behavioural and Minimally Invasive Therapy — A Urologist’s View

C. Chapple, K. Andersson, S. Bhargava, 2005 .

Application of guidelines to the evaluation of the male patient with urgency and/or incontinence

C. Chapple, A. Mangera, 2014, Current opinion in urology.

Contemporary Combination Therapy in the Treatment of LUTS/BPH

N. Osman, C. Chapple, 2013, Current Bladder Dysfunction Reports.

Current pharmacotherapy of lower urinary tract symptoms

C. Chapple, K. Andersson, 2011 .

Overview of Evidence for Contemporary Management of Lower Urinary Tract Symptoms Presumed Due to Benign Prostatic Hyperplasia in Males

C. Chapple, 2010 .

BMJ Learning: Benign prostatic hyperplasia: treatment in primary care

C. Chapple, A. Patel, 2006, BMJ : British Medical Journal.

Acute urinary retention: Who is at risk and how best to manage it?

C. Chapple, A. Patel, 2006, Current urology reports.

Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL).

M. Michel, C. Chapple, 2006, European urology.

Christopher R Chapple primary care Benign prostatic hyperplasia : treatment in

C. Chapple, A. Patel, 2006 .

Overactive bladder and underactive bladder: A symptom syndrome or urodynamic diagnosis?

C. Chapple, 2013, Neurourology and urodynamics.

OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity

R. Dmochowski, C. Chapple, W. Lam, 2011, Neurourology and urodynamics.

Overactive bladder symptoms and voiding dysfunction in neurologically normal women

L. Cardozo, C. Chapple, M. Espuña-Pons, 2012, Neurourology and urodynamics.

Pathophysiology of the lower urinary tract and CNS.

C. Chapple, 2011, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Depressed contractile responses to neurokinin A in idiopathic but not neurogenic overactive human detrusor muscle.

R. Chess-Williams, C. Chapple, D. Sellers, 2006, European urology.

A prospective, randomized, double‐blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome

C. Chapple, C. Ryan, S. Bates, 2007, BJU international.

Urologic Principles and Practice

W. Steers, C. Chapple, C. P. Evans, 2020 .

Vaginal surgery for incontinence and prolapse

P. Norton, P. Zimmern, C. Chapple, 2006 .

Contemporary management of urethral trauma and the post-traumatic stricture.

C. Chapple, D. Png, Christopher R. Chapple, 1999, Current opinion in urology.

Consensus statement on urethral trauma

A. Mundy, G. Jordan, V. Pansadoro, 2004, BJU international.

Non-invasive transcutaneous electrical stimulation in the treatment of overactive bladder

Christopher R. Chapple, Anthony T. Barker, Martin Slovak, 2015, Asian journal of urology.

Which muscarinic receptor is important in the bladder?

R. Chess-Williams, C. Chapple, T. Yamanishi, 2001, World Journal of Urology.

The value of prostate specific antigen (PSA) density and free: total PSA ratio in selecting patients with a normal digital rectal examination and intermediate total PSA levels for further investigation.

H. Woo, H. Klingler, D. Rosario, 1998, British journal of urology.

Screening and Diagnostic Considerations in Benign Prostatic Hyperplasia

C. Chapple, N. Bryan, 1997 .

Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype.

C. Chapple, I. Marshall, R. P. Burt, 1995, British journal of pharmacology.

The UroLume stent in the management of benign prostatic hyperplasia.

C. Chapple, E. Milroy, 1993, The Journal of urology.

A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment.

R. Dmochowski, L. Cardozo, B. Peyronnet, 2019, European urology.

Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.

L. Cardozo, C. Chapple, F. Haab, 2005, European urology.

Potassium‐magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis

C. Chapple, 1998 .

European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era☆

M. Babjuk, A. Mottrie, A. Salonia, 2020, European Urology.

Bladder calculus formation as a complication of the Stamey procedure.

C. Chapple, D. Ralph, E. Milroy, 1990, British journal of urology.

Permanently implanted urethral stent for prostatic obstruction in the unfit patient. Preliminary report.

C. Chapple, E. Milroy, D. Rickards, 1990, British journal of urology.

A NEW TREATMENT FOR URETHRAL STRICTURES

C. Chapple, J. Cooper, E. Milroy, 1988, The Lancet.

Tissue engineered buccal mucosa for urethroplasty: progress and future directions.

S. MacNeil, N. Osman, C. Chapple, 2015, Advanced drug delivery reviews.

Hyperammonemic Encephalopathy Approximately 40 Years after Urinary Diversion for Bladder Exstrophy: A Case Report

C. Chapple, D. Yates, G. McKenzie, 2011, Current Urology.

SIU/ICUD Consultation on Urethral Strictures: The management of anterior urethral stricture disease using substitution urethroplasty.

A. Atala, C. Chapple, G. Barbagli, 2014, Urology.

Defining a patient-reported outcome measure for urethral stricture surgery.

A. Mundy, J. N'Dow, C. Chapple, 2011, European urology.

What is the evidence for the management of urethral amyloidosis? A systematic review of the literature

M. Fernando, C. Chapple, A. Mangera, 2012, BJU international.

A systematic review of graft augmentation urethroplasty techniques for the treatment of anterior urethral strictures.

C. Chapple, A. Mangera, J. Patterson, 2011, European urology.

Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement

F. Montorsi, F. Zattoni, W. Artibani, 2013, World Journal of Urology.

Tissue engineering: recent advances and review of clinical outcome for urethral strictures

N. Osman, C. Chapple, S. Saad, 2021, Current opinion in urology.

Current state of urethral tissue engineering.

N. Osman, N. Mangır, C. Chapple, 2019, Current opinion in urology.

Tissue engineering of the urethra: where are we in 2019?

C. Chapple, 2019, World Journal of Urology.

Overcoming scarring in the urethra: Challenges for tissue engineering

S. MacNeil, C. Chapple, A. Şimşek, 2018, Asian journal of urology.

Recent advances in understanding urethral lichen sclerosus

N. Osman, C. Chapple, A. Mangera, 2016, F1000Research.

Flexible cystourethroscopy in the follow-up of posturethroplasty patients and characterisation of recurrences.

N. Osman, C. Chapple, C. Hillary, 2015, European urology.

WITHDRAWN: Current trends in urethral stricture management

N. Osman, C. Chapple, C. Hillary, 2014 .

Current trends in urethral stricture management

N. Osman, C. Chapple, C. Hillary, 2014, Asian journal of urology.

A systematic review of surgical techniques used in the treatment of female urethral stricture.

N. Osman, C. Chapple, A. Mangera, 2013, European urology.

Developing tissue-engineered solutions for the treatment of extensive urethral strictures.

S. MacNeil, N. Osman, C. Chapple, 2013, European urology.

Tissue engineering in urethral reconstruction--an update.

C. Chapple, A. Mangera, 2013, Asian journal of andrology.

Reply to Alchiede Simonato and Andrea Gregori's Letter to the Editor re: Altaf Mangera, Jacob M. Patterson, Christopher R. Chapple. A Systematic Review of Graft Augmentation Urethroplasty Techniques for the Treatment of Anterior Urethral Strictures. Eur Urol 2011;59:797–814

C. Chapple, A. Mangera, J. Patterson, 2011 .

Methods to reduce the contraction of tissue-engineered buccal mucosa for use in substitution urethroplasty.

S. MacNeil, C. Chapple, A. Bullock, 2011, European urology.

Management of anterior urethral stricture: an evidence-based approach

C. Chapple, A. Mangera, 2010, Current opinion in urology.

Tissue-engineered buccal mucosa urethroplasty-clinical outcomes.

S. MacNeil, C. Chapple, S. Bhargava, 2008, European urology.

Surgical techniques in substitution urethroplasty using buccal mucosa for the treatment of anterior urethral strictures.

C. Chapple, J. Patterson, 2008, European urology.

Evaluating Alternative Materials for the Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse: A Comparison of the In Vivo Response to Meshes Implanted in Rabbits.

S. MacNeil, J. Deprest, G. Callewaert, 2016, The Journal of urology.

Biodegradable scaffolds designed to mimic fascia-like properties for the treatment of pelvic organ prolapse and stress urinary incontinence

S. MacNeil, N. Mangır, C. Chapple, 2016, Journal of biomaterials applications.

Silodosin: a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia

F. Montorsi, N. Osman, C. Chapple, 2012, Expert opinion on pharmacotherapy.

Urodynamic assessment of the bashful bladder.

H. Woo, D. Rosario, C. Chapple, 2000, The Journal of urology.

Xanthogranulomatous pyelonephritis. A reappraisal and immunohistochemical study.

J. Crocker, J. Newman, C. Chapple, 1988, Archives of pathology & laboratory medicine.

Pharmacological Treatment of Urinary Incontinence Chairman

L. Cardozo, C. Chapple, H. Drutz, 2005 .

TRPV1 enhances the afferent response to P2X receptor activation in the mouse urinary bladder

R. Chess-Williams, D. Grundy, C. Chapple, 2018, Scientific Reports.

A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder.

C. Roehrborn, C. Chapple, 2006, European urology.

Ectopic human chorionic gonadotrophin (HCG) production: is the detection by serum analysis of HCG of clinical relevance in transitional cell carcinoma of the bladder?

H. J. Evans, J. Newman, C. Chapple, 1994, British journal of urology.

Ectopic beta-human chorionic gonadotropin production by bladder urothelial neoplasia.

J. Crocker, C. Chapple, J. O'Brien, 1986, Archives of pathology & laboratory medicine.

Production of #-human chorionic gonadotropin by prostatic adenocarcinoma and transitional cell carcinoma of the upper urinary tract

J. Crocker, C. Chapple, J. Newman, 2007 .

Production of beta-human chorionic gonadotropin by prostatic adenocarcinoma and transitional cell carcinoma of the upper urinary tract.

J. Crocker, C. Chapple, J. Newman, 1987, British journal of experimental pathology.

The Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management: Introduction and Conclusions

C. Chapple, 2003 .

W 7 : Detrusor underactivity : detection and diagnosis

M. Oelke, C. Chapple, K. Rademakers, 2014 .

Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder

Gary Kay, P. Pasricha, A. Laties, 2006, British journal of pharmacology.

Anatomy and Innervation of the Prostate Gland

C. Chapple, 1994 .

Vesicoureteric reflux in the adult male.

T. Christmas, C. Chapple, R. Turner-Warwick, 1990, British journal of urology.

Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.

A. Tubaro, C. Chapple, M. Brodsky, 2007, European urology.

The placebo effect in overactive bladder syndrome

C. Chapple, Z. Kopp, A. Mangera, 2011, Nature Reviews Urology.

The contemporary pharmacological management of overactive bladder

C. Chapple, C. Chapple, 2006 .

Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004).

C. Chapple, S. Raines, A. Patroneva, 2006, European urology.

The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis.

Z. Gabriel, C. Chapple, V. Khullar, 2005, European urology.

Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow.

P. Abrams, C. Chapple, 2005, European urology.

Isolated human bladder: evidence for an adenine dinucleotide acting on P2X-purinoceptors and for purinergic transmission.

G. Burnstock, C. Chapple, C. Hoyle, 1989, European journal of pharmacology.

Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

C. Roehrborn, C. Stief, M. Oelke, 2016, European urology.

Summary of Anticholinergic Pharmacotherapy Available for Overactive Bladder Dysfunction

C. Chapple, A. Mangera, 2012, Current Bladder Dysfunction Reports.

Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder

C. Chapple, 2006, Expert opinion on pharmacotherapy.

The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis.

Z. Gabriel, C. Chapple, V. Khullar, 2006, Urology.

The impact of overactive bladder on mental health, work productivity and health‐related quality of life in the UK and Sweden: results from EpiLUTS

K. Coyne, C. Chapple, I. Milsom, 2011, BJU international.

Validation of the urinary sensation scale (USS)

K. Coyne, M. Margolis, C. Chapple, 2011, Neurourology and urodynamics.

Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.

E. Mueller, D. Staskin, C. Gratzke, 2019, European urology.

Double-blind, placebo-controlled, cross-over study of flavoxate in the treatment of idiopathic detrusor instability.

C. Chapple, E. Milroy, H. Parkhouse, 1990, British journal of urology.

Current and future trends in the management of overactive bladder

C. Chapple, A. Wagg, P. Toozs-Hobson, 2006, International Urogynecology Journal.

Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).

S. Kaplan, C. Schermer, K. McVary, 2020, The Journal of urology.

Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database

Christopher R. Chapple, Robert Snijder, Linda Cardozo, 2016, Contemporary clinical trials communications.

Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome

C. Chapple, M. Rosenberg, F. Brenes, 2009, BJU international.

Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.

K. Coyne, L. Brubaker, C. Chapple, 2006, Urology.

Solifenacin significantly improves all symptoms of overactive bladder syndrome

L. Cardozo, W. Steers, C. Chapple, 2006, International journal of clinical practice.

A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.

C. Chapple, L. Selvaggi, P. Toozs-Hobson, 2005, European urology.

Improved quality of life in patients with overactive bladder symptoms treated with solifenacin

L. Cardozo, C. Kelleher, C. Chapple, 2005, BJU international.

A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder

P. Abrams, W. Steers, P. Norton, 2005, BJU international.

The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects

L. Cardozo, W. Artibani, C. Chapple, 2005, BJU international.

A Narrative Review of Patient-reported Outcomes in Overactive Bladder: What is the Way of the Future?

C. Kelleher, Morgan Mako, C. Chapple, 2016, European urology.

Comparison of fesoterodine and tolterodine in patients with overactive bladder

K. Jünemann, C. Chapple, M. Brodsky, 2008, BJU international.

Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome

P. Abrams, L. Cardozo, C. Chapple, 2006, International journal of urology : official journal of the Japanese Urological Association.

Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta‐analysis

V. Nitti, C. Chapple, M. Drake, 2017, BJU international.

Antimuscarinic Treatments in Overactive Bladder

C. Chapple, Z. Kopp, D. Muston, 2010 .

Open to debate. The Motion: antimuscarinics are the mainstay of therapy for overactive bladder.

C. Chapple, F. Cruz, 2008, European urology.

Classification of Mixed Incontinence

C. Chapple, 2006 .

Developments in pharmacological therapy for the overactive bladder

C. Chapple, E. Gormley, 2006, BJU international.

Interview with Chris Chapple. Overactive bladder: tackling the problem.

C. Chapple, 2006, European urology.

A review of adherence to drug therapy in patients with overactive bladder

L. Cardozo, P. van Kerrebroeck, C. Kelleher, 2008, BJU international.

[Urinary incontinence in the elderly: what can and should be done?].

A. Stenzl, J. Bedke, C. Chapple, 2013, Der Urologe. Ausg. A.

Overactive bladder syndrome in older people

L. Cardozo, C. Kelleher, D. de Ridder, 2007, BJU international.

YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a european placebo- and tolterodinge-conrolled, phase-II, dose-finding study

G. Kramer, D. Ridder, C. Chapple, 2002 .

Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability

L. Cardozo, V. Nitti, C. Chapple, 2014, Neurourology and urodynamics.

Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.

Arun Mistry, C. Chapple, R. Scarpa, 2007, European urology.

New once‐daily formulation for trospium in overactive bladder

C. Chapple, 2010, International journal of clinical practice.

Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double‐blind, placebo‐controlled EIGHT trial

C. Chapple, F. Haab, E. Mangan, 2014, BJU international.

Another Therapeutic Role for Intravesical Botulinum Toxin: Patients with Long-stay Catheters and Refractory Bladder Pain and Catheter Bypass Leakage.

N. Osman, C. Chapple, A. Mangera, 2020, European urology focus.

What is the feasibility of switching to 200IU OnabotulinumtoxinA in patients with detrusor overactivity who have previously received 300IU?

C. Chapple, A. Mangera, R. Inman, 2014, Central European journal of urology.

What Is the Evidence for the Use of Botulinum Toxin in Idiopathic Detrusor Overactivity?

C. Chapple, A. Mangera, 2011 .

Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results.

C. Chapple, J. Patterson, A. Patel, 2006, European urology.

Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.

C. Kelleher, S. Aballéa, C. Chapple, 2018, European urology.

Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).

M. Stölzel, S. Herschorn, Tahir Saleem, 2016, European urology.

Development of an overactive bladder assessment tool (BAT): A potential improvement to the standard bladder diary

Y. Homma, C. Kelleher, C. Chapple, 2018, Neurourology and urodynamics.

Corrigendum to: “Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder” [Eur Urol 2007;52:1204–12]

A. Tubaro, C. Chapple, M. Brodsky, 2008 .

Management of neurogenic bladder in patients with Parkinson's disease: A systematic review

H. Salehi-pourmehr, C. Chapple, S. Hajebrahimi, 2018, Neurourology and urodynamics.

A proof‐of‐concept study: Mirabegron, a new therapy for overactive bladder

G. Amarenco, O. Yamaguchi, C. Chapple, 2013, Neurourology and urodynamics.

OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

C. Nardo, P. Radziszewski, C. Chapple, 2013, European urology.

β3-agonist therapy: a new advance in the management of overactive bladder?

C. Chapple, 2012, European urology.

Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial.

R. Dmochowski, M. Chancellor, V. Nitti, 2010, The Journal of urology.

Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies

M. Oelke, V. Nitti, A. Tubaro, 2017, Therapeutic advances in urology.

Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.

M. Speakman, C. Chapple, M. Drake, 2013, European urology.

Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.

V. Nitti, S. Herschorn, M. B. Blauwet, 2015, European urology.

(−)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide (A-278637): A Novel ATP-Sensitive Potassium Channel Opener Efficacious in Suppressing Urinary Bladder Contractions. I. In Vitro Characterization

J. Sullivan, R. Chess-Williams, M. Williams, 2002, Journal of Pharmacology and Experimental Therapeutics.

Long‐term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

P. Abrams, E. Mueller, C. Gratzke, 2019, Neurourology and urodynamics.

Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?

L. Cardozo, S. Herschorn, C. Chapple, 2017, International Urogynecology Journal.

Antimuscarinic agents in elderly people

C. Chapple, A. Mangera, 2010, International journal of clinical practice.

An Improved In Vivo Methodology to Visualise Tumour Induced Changes in Vasculature Using the Chick Chorionic Allantoic Membrane Assay.

S. MacNeil, J. Haycock, N. Mangır, 2018, In vivo.

Clinical proof of concept study (blossom) shows novel beta 3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder

O. Yamaguchi, C. Chapple, A. Mattiasson, 2008 .

Prostate Surgery for Men with Lower Urinary Tract Symptoms: Do We Need Urodynamics to Find the Right Candidates? Exploratory Findings from the UPSTREAM Trial

C. Metcalfe, G. Young, P. Blair, 2021, European urology focus.

Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States.

K. Coyne, M. Kvasz, C. Chapple, 2012, European urology.

The use of implanted materials for treating women with pelvic organ prolapse and stress urinary incontinence.

S. MacNeil, C. Chapple, 2019, Current opinion in urology.

The underactive bladder: detection and diagnosis

N. Osman, C. Chapple, C. Hillary, 2016, F1000Research.

Botulinum toxin--new mechanisms, new therapeutic directions?

C. Chapple, A. Patel, 2006, European urology.

Updated systematic review and meta-analysis of the comparative data on colposuspensions, pubovaginal slings, and midurethral tapes in the surgical treatment of female stress urinary incontinence.

M. Barber, V. Ficarra, D. Waltregny, 2010, European urology.

Management strategies and outcome of ureterovaginal fistulae: A systematic review and meta‐analysis

A. Mandal, C. Chapple, A. Bhadoria, 2022, Neurourology and urodynamics.

The use of 2 ipsilateral ureteral stents for relief of ureteral obstruction from extrinsic compression

C. Chapple, 1998 .

Long‐term follow‐up of a multicentre randomised controlled trial comparing tension‐free vaginal tape, xenograft and autologous fascial slings for the treatment of stress urinary incontinence in women

S. Emery, C. Chapple, A. Nambiar, 2015, BJU international.

Fourth international consultation on incontinence recommendations of the international scientific committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence

C. Dubeau, R. Dmochowski, L. Cardozo, 2010, Neurourology and urodynamics.

Case Discussion: Vesicovaginal Fistula Following a Total Abdominal Hysterectomy: The Case for Abdominal Repair.

C. Chapple, A. Mangera, 2016, European urology focus.

Female Incontinence

J. Bosch, C. Chapple, T. Hanuš, 2000, European Urology.

An estradiol releasing, proangiogenic hydrogel as a candidate material for use in soft tissue interposition

S. MacNeil, V. Hasırcı, N. Mangır, 2019, Neurourology and urodynamics.

The Aetiology, Treatment, and Outcome of Urogenital Fistulae Managed in Well- and Low-resourced Countries: A Systematic Review.

N. Osman, P. Hilton, C. Chapple, 2016, European urology.

Urethral Diverticula, Urethro-Vaginal Fistulae, Vesico-Vaginal Fistulae

C. Chapple, 2003 .

Contemporary Outcomes of Surgery for Primary and Recurrent Genitourinary Fistulae in a Well-resourced Country

N. Osman, C. Chapple, C. Hillary, 2021, European urology open science.

Functional and reconstructive urology (part one)

C. Chapple, Chuanliang Xu, Q. Fu, 2018, Asian journal of urology.

Pelvic floor spasm as a cause of voiding dysfunction

L. Ng, T. Kuo, C. Chapple, 2015, Current opinion in urology.

Design and validation of a new screening instrument for lower urinary tract dysfunction: the bladder control self-assessment questionnaire (B-SAQ).

L. Cardozo, P. van Kerrebroeck, M. Hohenfellner, 2007, European urology.

The Midurethral Fascial "Sling on a String": An Alternative to Midurethral Synthetic Tapes in the Era of Mesh Complications.

N. Osman, C. Chapple, C. Hillary, 2018, European urology.

What was hot at the joint ICS and IUGA meeting Toronto, Canada, 23–27 August 2010

C. Chapple, K. Tikkinen, A. Mangera, 2011, Neurourology and urodynamics.

Synthetic Materials Used in the Surgical Treatment of Pelvic Organ Prolapse: Problems of Currently Used Material and Designing the Ideal Material

S. MacNeil, N. Mangır, C. Chapple, 2018, Pelvic Floor Disorders.

Biomaterials for Pelvic Floor Reconstructive Surgery: How Can We Do Better?

S. MacNeil, N. Osman, C. Chapple, 2015, BioMed research international.

Rising awareness of the complications of synthetic slings

C. Chapple, S. Bhargava, 2004, Current opinion in urology.

A landmark in cooperation

C. Chapple, M. Karram, 2009, International Urogynecology Journal.

Urodynamics in the management of female stress incontinence - which test and when?

C. Chapple, A. Patel, 2008, Current opinion in urology.

Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.

F. Montorsi, P. Albers, M. Roobol, 2019, European urology.

“Pelvic Organ Prolapse Quantification System (POP-Q)-A New Era in Pelvic Prolapse Staging” (2011), by Cristian Persu, Christopher Chapple, Victor Cauni, Stefan Gutue, and Petrisor Geavlete

C. Chapple, P. Geavlete, V. Cauni, 2021 .

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder

C. Nardo, V. Nitti, S. Herschorn, 2014, International journal of clinical practice.

Recent advances in basic science for overactive bladder

R. Chess-Williams, C. Chapple, Rebecca L. Cross, 2005, Current opinion in urology.

296 Distribution of purinergic receptors in urinary bladder of porcine and normal human urinary bladder

R. Chess-Williams, C. Chapple, Vivekanandan Kumar, 2004 .

295 Purinergic activity in sensory disorders of the bladder

R. Chess-Williams, D. Rosario, C. Chapple, 2004 .

Underactive bladder: Pathophysiology and clinical significance

N. Osman, C. Chapple, Reem Aldamanhori, 2017, Asian journal of urology.

Underactive bladder, detrusor underactivity, definition, symptoms, epidemiology, etiopathogenesis, and risk factors

C. Chapple, Reem Aldamanhori, 2017, Current opinion in urology.

The underactive bladder: a new clinical concept?

G. V. van Koeveringe, N. Osman, M. Oelke, 2015, European urology.

Regenerative medicine and injection therapies in stress urinary incontinence

S. MacNeil, A. Stenzl, C. Chapple, 2020, Nature Reviews Urology.

09 : 25 09 : 30 Discussion All 09 : 30 09 : 50 Evaluation and diagnosis

C. Chapple, D. Castro-Diaz, T. Tarcan, 2013 .

Mesh sling in an era of uncertainty: lessons learned and the way forward.

P. Zimmern, L. Brubaker, C. Chapple, 2013, European urology.

Considerations in the modern management of stress urinary incontinence resulting from intrinsic sphincter deficiency

N. Osman, C. Chapple, C. Hillary, 2015, World Journal of Urology.

Application of Tissue Engineering to Pelvic Organ Prolapse and Stress Urinary Incontinence

S. MacNeil, N. Osman, C. Chapple, 2015, Lower urinary tract symptoms.

Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms

L. Cardozo, C. Chapple, M. Drake, 2014, BJU international.

The Role of Urodynamics in the Evaluation of Urinary Incontinence: The European Association of Urology Recommendations in 2016.

F. Burkhard, C. Chapple, G. Lemack, 2017, European urology.

Invasive urodynamic testing prior to surgical treatment for stress urinary incontinence in women: cost-effectiveness and value of information analyses in the context of a mixed methods feasibility study

E. McColl, D. Howel, Jing Shen, 2018, Pilot and Feasibility Studies.

INVESTIGATE-I (INVasive Evaluation before Surgical Treatment of Incontinence Gives Added Therapeutic Effect?): study protocol for a mixed methods study to assess the feasibility of a future randomised controlled trial of the clinical utility of invasive urodynamic testing

M. Deverill, E. McColl, D. Howel, 2011, Trials.

Oestradiol-releasing Biodegradable Mesh Stimulates Collagen Production and Angiogenesis: An Approach to Improving Biomaterial Integration in Pelvic Floor Repair.

S. MacNeil, N. Mangır, C. Chapple, 2017, European urology focus.

Systematic Review and Meta-analysis of Candidate Gene Association Studies of Lower Urinary Tract Symptoms in Men

P. Rajan, T. Palmer, M. Järvelin, 2014, European urology.

Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.

M. Roobol, M. Wirth, J. Catto, 2021, European urology.

Is a voiding diary really necessary in 2014?

C. Chapple, 2014, European urology.

Management of Overactive Bladder

A. Wein, C. Chapple, 2012 .

Delayed repair of pelvic fracture urethral injuries: Preoperative decision-making

N. Osman, C. Chapple, A. Mangera, 2015, Arab journal of urology.

Current Concepts of Anterior Urethral Pathology: Management and Future Directions

C. Chapple, A. Mangera, 2011 .

Detrusor Underactivity and the Underactive Bladder: A Systematic Review of Preclinical and Clinical Studies.

F. Esperto, N. Osman, C. Chapple, 2018, European urology.

Tissue Engineering and Cell Therapy for Underactive Bladder: Current and Future Approaches

N. Osman, C. Chapple, Reem Aldamanhori, 2017 .

Overview consensus statement.

S. Bauer, R. Dmochowski, L. Cardozo, 2002, Urology.

Female urethral diverticula

C. Chapple, A. Patel, 2006, Current opinion in urology.

The contemporary clinical treatment of female stress incontinence

K. Kreder, C. Chapple, D. Smith, 1994, International Urogynecology Journal.

Qualitative Exploration of the Patient Experience of Underactive Bladder.

C. Chapple, C. Harding, C. Hillary, 2017, European urology.

Introduction: The Clinical Problem

C. Chapple, 1994 .

A follow up on transurethral collagen injection therapy for urinary incontinence

C. Chapple, 1998 .

Male Urinary Incontinence: Assessment and Management

N. Osman, C. Chapple, 2020 .

Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.

D. Murphy, A. Heidenreich, S. Herschorn, 2019, European urology.

CHARACTERISTICS OF ADENOSINE TRIPHOSPHATASE RELEASE FROM PORCINE AND HUMAN NORMAL BLADDER

R. Chess-Williams, C. Chapple, Vivekanandan Kumar, 2004 .

Regeneration of Degenerated Urinary Sphincter Muscles: Improved Stem Cell-Based Therapies and Novel Imaging Technologies

U. Kramer, A. Stenzl, W. Feitz, 2015, Cell transplantation.

A critical review of diagnostic criteria for evaluating patients with symptomatic stress urinary incontinence

A. Wein, L. Brubaker, W. Artibani, 2005, BJU international.

Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.

L. Cardozo, D. Staskin, S. Herschorn, 2019, European urology.

Systematic review and meta‐analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine

S. Serni, G. Morgia, S. Kaplan, 2018, International journal of urology : official journal of the Japanese Urological Association.

Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)

P. Abrams, S. Herschorn, D. Robinson, 2017, BJU international.

An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.

P. Dasgupta, C. Roehrborn, A. Apostolidis, 2014, European urology.

Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder.

S. Colman, V. Nitti, C. Chapple, 2008, Urology.

It's just the worry about not being able to control it! A qualitative study of living with overactive bladder.

C. Kelleher, C. Chapple, Z. Kopp, 2008, British journal of health psychology.

Basic mechanisms of urgency: preclinical and clinical evidence.

M. Michel, C. Chapple, 2009, European urology.

Spontaneous contractions of the pig urinary bladder: the effect of ATP‐sensitive potassium channels and the role of the mucosa

R. Chess-Williams, C. Chapple, H. Akino, 2008, BJU international.

Prazosin in the Treatment of Prostatic Obstruction: A Placebo-Controlled Study

R. Kirby, C. Chapple, E. Milroy, 1989 .

Management of the patient with failed hypospadias surgery presenting in adulthood

C. Chapple, Reem Aldamanhori, 2017, F1000Research.

A mixed methods study to assess the feasibility of a randomised controlled trial of invasive urodynamic testing versus clinical assessment and non-invasive tests prior to surgery for stress urinary incontinence in women: the INVESTIGATE-I study

E. McColl, D. Howel, Jing Shen, 2015, Trials.

INVESTIGATE-I (INVasive Evaluation before Surgical Treatment of Incontinence Gives Added Therapeutic Effect?): a mixed-methods study to assess the feasibility of a future randomised controlled trial of invasive urodynamic testing prior to surgery for stress urinary incontinence in women.

E. McColl, D. Howel, Jing Shen, 2015, Health technology assessment.

Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms.

R. Dmochowski, G. Novara, E. Agro', 2019, European urology.

a 1-Adrenoceptor antagonist Adrenergic b 3 receptor agonists Antimuscarinics Benign prostatic hyperplasia Overactive bladder

R. Dmochowski, G. Novara, E. Agro', 2018 .

The role of co‐medication in the treatment of OAB

N. Osman, C. Chapple, 2015 .

Lower urinary tract symptoms revisited: a broader clinical perspective.

C. Roehrborn, S. Kaplan, R. Dmochowski, 2008, European urology.

Monotherapy with α-blocker or phosphodiesterase 5 inhibitor for lower urinary tract symptoms?

C. Chapple, 2012, European urology.

Transitional cell carcinoma of the upper renal tract in rubber workers.

J. Newman, C. Chapple, J. O'Brien, 1985, Postgraduate medical journal.

Renal adenocarcinoma in young adults.

C. Chapple, E. Milroy, J. Noble, 1994, Urologia internationalis.

Urinary tract metastasis from renal carcinoma.

M. Falzon, C. Chapple, W. Hendry, 1992, British journal of urology.

Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.

C. Chapple, 1996, European urology.

Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation.

G. Burnstock, C. Chapple, P. Greengrass, 1989, British journal of urology.

Relationship between overactive bladder (OAB) and irritable bowel syndrome (IBS): concurrent disorders with a common pathophysiology?

C. Chapple, D. Daly, 2013, BJU international.

Bladder afferent sensitivity in wild‐type and TRPV1 knockout mice

D Grundy, R. Chess-Williams, D. Grundy, 2007, The Journal of physiology.

Induction of oxidative stress causes functional alterations in mouse urothelium via a TRPM8-mediated mechanism: implications for aging

D. Grundy, C. Chapple, D. Daly, 2014, Aging cell.

What is the clinical significance of urethroprostatic reflux as a radiological finding during videocystourethrography in neurologically normal patients?

S. Blease, C. Chapple, D. Rickards, 1990, European urology.

Subtrigonal phenol injection. How safe and effective is it?

C. Chapple, R. Turner-Warwick, P. Worth, 1991, British journal of urology.

Management of symptomatic urethral diverticula in women: a single-centre experience.

C. Chapple, R. Inman, F. Reeves, 2014, European urology.

Prostatic Obstruction: Pathogenesis And Treatment

C. Chapple, 2011 .

Chronic urinary retention in men: how we define it, and how does it affect treatment outcome

N. Osman, C. Chapple, 2013, BJU international.

Dendritic Cell-Based Immunotherapy of Renal Cell Carcinoma

M. Mbizvo, H. Gill, A. G. Johnson, 1998, Urologia Internationalis.

Alfuzosinof the Therapeutic Use of the Prolonged-Release Formulation Given Once Daily in the Management of Benign Prostatic Hyperplasia

T. Tammela, C. Chapple, C. Mey, 2002 .

Cardiac stress during transurethral prostatectomy: Authors' reply

C. Chapple, J. M. Walker, E. Milroy, 1992 .

Faculty Opinions recommendation of SIU/ICUD Consultation On Urethral Strictures: Epidemiology, etiology, anatomy, and nomenclature of urethral stenoses, strictures, and pelvic fracture urethral disruption injuries.

N. Mangır, C. Chapple, 2020 .

Surgical tips and tricks during urethroplasty for bulbar urethral strictures focusing on accurate localisation of the stricture: results from a tertiary centre.

T. Kuo, C. Chapple, R. Inman, 2015, European Urology.

Functional and reconstructive urology (part two)

C. Chapple, Chuanliang Xu, Q. Fu, 2018, Asian Journal of Urology.

1741: Second Messenger Pathway Involved in Contraction of the Female Pig Urethra upon Stimulation of α1 –Adrenoceptors

R. Chess-Williams, C. Chapple, R. L. Scott, 2004 .

Renal infarction following spontaneous renal vein thrombosis in the puerperium

D. Rosario, C. Chapple, Stphen C. Radley, 1999, British journal of obstetrics and gynaecology.

Segmental up‐regulation of transforming growth factor beta in the pathogenesis of primary megaureter: an immunohistochemical study

C. Chapple, 1998 .

A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature.

C. Roehrborn, C. Stief, R. Dmochowski, 2009, European urology.

Contemporary outcomes of hypospadias retrieval surgery in adults

N. Osman, C. Chapple, R. Inman, 2018, BJU international.

The assessment of a novel Transdermal Amplitude Modulated Signal recently introduced for the treatment of Overactive Bladder symptoms

A. Barker, C. Chapple, M. Slovák, 2017 .

WITHDRAWN: Non-invasive transcutaneous electrical stimulation in the treatment of overactive bladder

A. Barker, C. Chapple, M. Slovák, 2014 .

The assessment of a novel electrical stimulation waveform recently introduced for the treatment of overactive bladder

A. Barker, C. Chapple, M. Slovák, 2013, Physiological Measurement.

A multicenter, double-blind, randomized, parallel group study comparing polyvinyl chloride and polyvinyl chloride-free catheter materials.

J. Witjes, M. Marberger, C. Chapple, 2009, The Journal of urology.

Botulinum Toxin Versus Neural Stimulation.

N. Osman, C. Chapple, 2017, European Urology Focus.

Oral Pain and Morbidity with Buccal Mucosa Grafts for Substitution Urethroplasty: Closure or Not.

C. Chapple, 2018, European urology.

Endopyelotomy for primary ureteropelvic junction obstruction: risk factors determine the success rate

C. Chapple, 1998 .

The Evaluation and Treatment of Adult Nocturnal Enuresis

C. Chapple, C. Hillary, 2014, Current Bladder Dysfunction Reports.

The basis for drug treatment of the overactive bladder

A. Wein, C. Chapple, K. Andersson, 2001, World Journal of Urology.

Adenocarcinoma in the free wall of a simple renal cyst.

J. Newman, C. Chapple, J. O'Brien, 1987, Journal of the Royal College of Surgeons of Edinburgh.

Evaluation and management of anterior urethral stricture disease

N. Osman, C. Chapple, A. Mangera, 2016, F1000Research.

Contemporary surgical management of female urethral stricture disease

N. Osman, C. Chapple, 2015, Current opinion in urology.

The ultrasound cystodynamogram--a new radiological technique.

T. Christmas, C. Chapple, D. Rickards, 1990, The British journal of radiology.

A new stent for the treatment of urethral strictures. Preliminary report.

C. Chapple, E. Milroy, A. Eldin, 1989, British journal of urology.

Management of the failure of a permanently implanted urethral stent-a therapeutic challenge.

C. Chapple, S. Bhargava, 2008, European urology.

Anterior urethral surgery: current concepts and future directions.

C. Chapple, 2010, European urology.

Functional Reconstruction of the Urinary Tract and Gynaeco-Urology

C. Chapple, R. Turner-Warwick, 2001 .

Functional reconstruction of the urinary tract

C. Chapple, 2000 .

OnabotulinumtoxinA for the treatment of overactive bladder

C. Chapple, A. Mangera, 2014 .

Duloxetine for male stress incontinence.

C. Chapple, 2006, European urology.

Stone formation on permanent suture material used previously in colposuspension.

H. Woo, D. Rosario, C. Chapple, 1995, British journal of urology.

The aging bladder insights from animal models

L. Birder, C. Chapple, A. Kullmann, 2017, Asian journal of urology.

What's topical in functional reconstruction and trauma--with particular reference to urethroplasty.

C. Chapple, 1999, Current opinion in urology.

Giant Hydronephrosis – A Diagnostic Dilemma

C. Chapple, J. Mountney, A. Johnson, 1998, Urologia Internationalis.

Mirabegron the first β3‐adrenoceptor agonist for overactive bladder (OAB): a summary of the phase III studies

C. Chapple, 2014, BJU international.

The first oral mucosal graft urethroplasty was carried out in the 19th century: the pioneering experience of Kirill Sapezhko (1857-1928).

D. Schultheiss, C. Chapple, D. Ilyin, 2012, European urology.

Development of two electronic bladder diaries: A patient and healthcare professionals pilot study

Ian Hosking, Altaf Mangera, Khawar Hameed, 2014, Neurourology and urodynamics.

Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM) for diagnosis and management of bladder outlet obstruction in men: study protocol for a randomised controlled trial

S. Noble, J. McGrath, J. Lane, 2015, Trials.

What was hot at the ICS meeting Glasgow, Scotland, 2011

C. Chapple, K. Tikkinen, A. Mangera, 2012, Neurourology and urodynamics.

Surgery for detrusor overactivity

C. Chapple, N. Bryan, 1998, World Journal of Urology.

The second‐line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin‐A in contemporary practice?

D. de Ridder, C. Chapple, 2009, BJU international.

Alpha antagonists-from initial concept to routine clinical practice.

C. Chapple, 2006, European urology.

Practical Functional Urology

D. Ridder, J. Heesakkers, F. Farag, 2016 .

Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome

K. Jünemann, P. Abrams, C. Chapple, 2012, World Journal of Urology.

Best practice in the use of onabotulinumtoxinA (BOTOX®) to optimize patient outcomes in overactive bladder

C. Chapple, 2014, Neurourology and urodynamics.

The development of the ICIQ‐UAB: A patient reported outcome measure for underactive bladder

B. Blok, G. V. van Koeveringe, M. Takei, 2019, Neurourology and urodynamics.

Urological Neurology and Urodynamics

H. Woo, D. Rosario, C. Chapple, 2000 .

Beta3-adrenoceptors in urinary bladder.

O. Yamaguchi, C. Chapple, 2007, Neurourology and urodynamics.

1367 ONABOTULINUMTOXINA IN PATIENTS WITH OVERACTIVE BLADDER AND URINARY INCONTINENCE: CONSISTENT EFFECT OVER REPEAT TREATMENT

C. Nardo, V. Nitti, C. Chapple, 2013 .

Crystallizing the Definition of Underactive Bladder Syndrome, a Common but Under‐recognized Clinical Entity

N. Osman, C. Chapple, 2015, Lower urinary tract symptoms.

Reply from author re: Stephan Madersbacher. OnabotulinumtoxinA for idiopathic overactive bladder symptoms: many answers but more questions. Eur Urol 2013;64:257-9: OnabotulinumtoxinA for idiopathic overactive bladder symptoms: some answers but even more questions.

C. Chapple, 2013, European urology.

Combination Pharmacotherapy for Overactive Bladder

C. Chapple, J. Park, 2018, Contemporary Pharmacotherapy of Overactive Bladder.

Intermittent androgen blockade in prostate cancer : rationale and clinical experience

C. Chapple, 2001 .

International Continence Society guidelines on urodynamic equipment performance.

C. Chapple, 2014, Neurourology and urodynamics.

Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy : A Randomised Double-blind Multicentre Phase 3 B Study ( BESIDE )

M. Stölzel, S. Herschorn, C. Chapple, 2016 .

Skin Substitutes: Burn Treatment and beyond

C. Chapple, H. Rennekampff, G. Greenleaf, 2012 .

Urgency as the cardinal symptom of overactive bladder: a critical analysis

L. Cardozo, A. Wein, C. Chapple, 2009, World Journal of Urology.

An unusual use for the arthroscope.

K. Porter, C. Chapple, 1984, Injury.

Prostatic urethral lift vs transurethral resection of the prostate: 2‐year results of the BPH6 prospective, multicentre, randomized study

U. Wetterauer, M. Speakman, C. Gratzke, 2017, BJU international.

Practical Urology: Essential Principles and Practice

William D. Steers, Christopher R. Chapple, W. Steers, 2011 .

Focus on nocturia in the elderly

N. Osman, C. Chapple, 2013 .

Lower urinary tract symptoms and urinary incontinence.

C. Chapple, A. Patel, 2009, The Ceylon medical journal.

The innervation of the human prostate gland--the changes associated with benign enlargement.

G. Burnstock, C. Chapple, J. Gosling, 1991, Journal of Urology.

The β3‐adrenoceptor mediates the inhibitory effects of β‐adrenoceptor agonists via the urothelium in pig bladder dome

C. Chapple, N. McKay, D. Sellers, 2010, Neurourology and urodynamics.

The Physiology of Micturition

C. Chapple, 1994 .

Urothelium derived inhibitory factor and cross-talk among receptors in the trigone of the bladder of the pig.

R. Chess-Williams, C. Chapple, L. Templeman, 2002, The Journal of urology.

Non-surgical treatment

E. McColl, D. Howel, Jing Shen, 2015 .

Developing biodegradable scaffolds for tissue engineering of the urethra

S. MacNeil, M. Selim, C. Chapple, 2011, BJU international.

Re: Guido Barbagli, Massimo Lazzeri. Clinical Experience with Urethral Reconstruction Using Tissue-engineered Oral Mucosa: A Quiet Revolution. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.05.043.

S. MacNeil, N. Osman, C. Chapple, 2015, European urology.

Specialist training in female urology and reconstructive urology: the UK experience

C. Chapple, M. Lucas, S. Harrison, 2007, Current Opinion in Urology.

The Modified Prone Jack-knife Position for the Excision of Female Urethral Diverticula.

N. Osman, N. Mangır, C. Chapple, 2020, European urology.

A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment

N. Thiruchelvam, A. Tubaro, C. Chapple, 2015, BJU international.

Inguinal bladder hernia associated with vesico-ureteric reflux.

T. Christmas, C. Chapple, D. Rickards, 1992, Postgraduate medical journal.

Formation of a urethral calculus around an unusual foreign body.

C. Chapple, J. Noble, 1993, British journal of urology.

Female Urethra: Is Ventral the True Dorsal?

N. Osman, C. Chapple, S. Saad, 2020, European urology.

Urethral stricture disease

C. Chapple, A. Mangera, 2005 .

Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies

L. Cardozo, F. Bunn, C. Kelleher, 2015, International journal of clinical practice.

Prevalence of Lower Urinary Tract Symptoms in China, Taiwan, and South Korea: Results from a Cross-Sectional, Population-Based Study

Shih-Ping Liu, C. Chapple, Kyu-Sung Lee, 2017, Advances in Therapy.

Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms

C. Roehrborn, S. Kaplan, R. Rosen, 2009, BJU international.

The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS

K. Coyne, A. Wein, A. Tubaro, 2009, BJU international.

Sleep Disorders, Comorbidities, Actions, Lower Urinary Tract Dysfunction, and Medications (“Sleep C.A.L.M.”) in the evaluation and management of nocturia: A simple approach to a complex diagnosis

R. Dmochowski, A. Wein, J. Lazar, 2023, Neurourology and urodynamics.

Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group.

L. Baert, C. Chapple, A. Spångberg, 1997, European urology.

Validation of the Overactive Bladder-Bladder Assessment Tool (OAB-BAT): A Potential Alternative to the Standard Bladder Diary for Monitoring OAB Outcomes.

Y. Homma, C. Kelleher, C. Chapple, 2021, European urology focus.

Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails.

D. Rosario, C. Chapple, J. Phillips, 2007, The Journal of urology.

Is Urethrotomy as Good as Urethroplasty in Men with Recurrent Bulbar Urethral Strictures?

N. Osman, C. Chapple, 2020, European urology.

Mitomycin C in the treatment of anterior urethral strictures

T. Kuo, C. Chapple, J. Park, 2018, Nature Reviews Urology.

A new treatment for urethral strictures: a permanently implanted urethral stent.

C. Chapple, E. Milroy, A. Eldin, 1989, The Journal of urology.

Randomised Prospective Trial of Contact Laser Prostatectomy (CLAP) versus Visual Laser Coagulation of the Prostate (VLAP) for the Treatment of Benign Prostatic Hyperplasia

C. Chapple, N. Bryan, K. Hastie, 2000, European Urology.

Contemporary concepts in the aetiopathogenesis of detrusor underactivity

N. Osman, C. Chapple, 2014, Nature Reviews Urology.

Journal club

C. Chapple, 2001, Journal of Neurology.

L A Comparison of Varying (cid:1) -Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms

C. Chapple, 2005 .

The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update.

C. Stief, S. Kaplan, C. Fowler, 2011, European urology.

The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia.

C. Chapple, D. Smith, D. Smith, 1994, British journal of urology.

Transurethral Needle Ablation (TUNATM)

H. Woo, M. Issa, C. Chapple, 1999, European Urology.

PRELIMINARY RESULTS OF THE EAU REAL-LIFE DATA REGISTRY ON TUNA® THERAPY

A. Tubaro, C. Chapple, H. Villavicencio, 2006 .

Effects of intravenous thyrotropin-releasing hormone on urethral closure pressure in females with voiding dysfunction.

H. Woo, D. Rosario, C. Chapple, 1995, European urology.

Systematic Review and Meta-Analysis of the Comparative Data on Colposuspensions , Pubovaginal Slings , and Midurethral Tapes in the Surgical Treatment of Female Stress Urinary Incontinence

M. Barber, V. Ficarra, D. Waltregny, 2010 .

What was “hot” at the ICS annual meeting San Francisco 2009

C. Chapple, R. Cartwright, Hashim Hashim, 2010, Neurourology and urodynamics.

Re: Dumoulin C, Hay-Smith J, Mac Habée-Séguin G, Mercier J. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women: A short version Cochrane systematic review with meta-analysis. Neurourol Urodyn, 2014

C. Chapple, 2014 .

Contemporary surgical management of stress urinary incontinence.

C. Chapple, 2020, Current opinion in urology.

Production of ascorbic acid releasing biomaterials for pelvic floor repair

S. MacNeil, N. Osman, N. Mangır, 2016, Acta biomaterialia.

Introduction and Concluding Remarks

C. Chapple, Christopher R. Chapple, 2000, European Urology.

BPH Disease Management: Satellite Symposium held at the 14th Congress of the European Association of Urology, Stockholm, April 1999: Proceedings

C. Chapple, 1999 .

BHP Disease Management. Introduction and concluding remarks.

C. Chapple, 1999, European urology.

Characteristics of patients presenting with LUTS/BPH in six European countries.

P. Teillac, R. Berges, A. Borkowski, 2006, European urology.

Lower urinary tract symptoms in men

C. Chapple, A. Patel, 2007, BMJ : British Medical Journal.

Increased sexual dysfunction in men with storage and voiding lower urinary tract symptoms.

C. Chapple, S. Morant, V. Vats, 2009, The journal of sexual medicine.

Health And Wellbeing Impact And Treatment of Nocturia – A Review of The Literature

N. Osman, C. Chapple, C. Hillary, 2014, EMJ Urology.

The ICS-'BPH' Study: the psychometric validity and reliability of the ICSmale questionnaire.

T. Peters, J. Donovan, P. Abrams, 1996, British journal of urology.

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction – Triumph: Design and Implementation

C. Chapple, 2001, European Urology.

The inhibitory role of acetylcholine and muscarinic receptors in bladder afferent activity.

R. Chess-Williams, D. Grundy, C. Chapple, 2010, European urology.

Frequency volume charts in the assessment and evaluation of treatment: how should we use them?

C. Chapple, N. Bryan, 2004, European urology.

Abstracts of the 15th Congress of the European Society for Urological Research, Istanbul, October 5–7, 2000

S. Loening, J. Moul, S. Srivastava, 2000, European Urology.

In vitro release of adenosine triphosphate from the urothelium of human bladders with detrusor overactivity, both neurogenic and idiopathic.

R. Chess-Williams, D. Rosario, C. Chapple, 2010, European urology.

Basic mechanisms of urgency: roles and benefits of pharmacotherapy

M. Michel, C. Chapple, 2009, World Journal of Urology.

Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human prostate.

G. Burnstock, C. Chapple, M. Phillips, 1989, The Journal of urology.

Evidence for a functional α1A‐ (α1C‐) adrenoceptor mediating contraction of the rat epididymal vas deferens and an α1B‐adrenoceptor mediating contraction of the rat spleen

C. Chapple, I. Marshall, R. P. Burt, 1995 .

Different subtypes of α1A‐adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053

C. Chapple, M. Hussain, I. Marshall, 1996, British journal of pharmacology.

Evidence for a functional alpha 1A- (alpha 1C-) adrenoceptor mediating contraction of the rat epididymal vas deferens and an alpha 1B-adrenoceptor mediating contraction of the rat spleen.

C. Chapple, I. Marshall, R. P. Burt, 1995, British journal of pharmacology.

à11AA-Adrenoceptor mediated contraction of rat prostatic vas deferens involves ryanodine Ca 2+ stores and Ca 2+ influx stimulated by diacylglycerol and PKC

C. Chapple, I. Marshall, R. P. Burt, 1998 .

Noradrenaline contractions of human prostate mediated by aClA-(cxlc) adrenoceptor subtype

C. Chapple, R. P. Burt, I. Marshall, 2006 .

Future drugs for the treatment of benign prostatic hyperplasia

C. Chapple, K. Andersson, K. Höfner, 2002, World Journal of Urology.

In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists.

J. Gever, A. Ford, R. Chess-Williams, 1999, British Journal of Pharmacology.

Latest Developments in the Field of Neurotransmitters

R. Chess-Williams, C. Chapple, 1998, European Urology.

Sources of Ca 2+ in contraction of rat portal vein to phenylephrine

C. Chapple, I. Marshall, R. P. Burt, 1997 .

Individual patient data from registrational trials of silodosin in the treatment of non‐neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data

F. Montorsi, G. Novara, C. Chapple, 2015, BJU international.

A twelve-week placebo-controlled study of prazosin in the treatment of prostatic obstruction.

T. Christmas, C. Chapple, E. Milroy, 1990, Urologia internationalis.

Overview on the lower urinary tract.

C. Chapple, 2011, Handbook of experimental pharmacology.

Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study)

F. Montorsi, G. Gandaglia, C. Chapple, 2016, International journal of urology : official journal of the Japanese Urological Association.

A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non‐neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)

F. Montorsi, G. Novara, C. Chapple, 2014, BJU international.

Advancing the Management of Overactive Bladder: New Data, New Directions

C. Chapple, 2007 .

Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups.

C. Chapple, R. Janknegt, 1993, European urology.

Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials.

C. Roehrborn, K. McVary, C. Chapple, 2015, European urology.

Alfuzosin for benign prostatic hypertrophy

C. Chapple, 1991, The Lancet.

Medical treatment for benign prostatic hyperplasia.

C. Chapple, 1992, Lancet.

A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction.

T. Christmas, P. Abrams, R. Kirby, 1994, British journal of urology.

Relaxant effects of potassium-channel openers on normal and hyper-reflexic detrusor muscle.

R. Chess-Williams, C. Chapple, S. Radley, 1998, British journal of urology.

Relaxant effects of potassium-channel openers on normal and hyper-reflexic detrusor muscle

R. Chess-Williams, C. Chapple, S. Radley, 1997 .

A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms.

C. Chapple, 2005, Reviews in urology.

Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.

P. Abrams, S. Herschorn, C. Chapple, 2009, European urology.

Lower urinary tract symptoms revisited.

C. Chapple, 2009, European urology.

Introduction and Concluding Remarks

C. Chapple, 1999, European Urology.

International Continence Society consensus on the diagnosis and treatment of nocturia

R. Dmochowski, P. Abrams, P. van Kerrebroeck, 2019, Neurourology and urodynamics.

Capsular perforation localisation and adenoma size as prognostic indicators of erectile dysfunction after transurethral prostatectomy

C. Chapple, 1998 .

Words of wisdom. Re: Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia.

C. Chapple, 2009, European urology.

Management of lower urinary tract symptoms in men: summary of NICE guidance

C. Chapple, Jennifer Hill, Clare Jones, 2010, BMJ : British Medical Journal.

Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals.

S. Noble, J. McGrath, J. Lane, 2020, European urology.

LUTS/BPH in clinical practice: the importance of nocturia and quality of sleep

E. Chartier-Kastler, C. Chapple, 2006 .

The Impact of Nocturia in Patients with LUTS/BPH: Need for New Recommendations☆

R. Berges, E. Chartier-Kastler, H. Stoevelaar, 2006 .

1076 Two year results of the BPH6 trial: A multi-center, prospective, randomized study of the prostatic urethral lift (PUL) vs transurethral resection of the prostate (TURP)

F. Montorsi, U. Wetterauer, M. Speakman, 2016 .

Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma

C. Chapple, 1998 .

Anatomy of the lower urinary tract

C. Chapple, A. Patel, 2008 .

Investigation and management of urinary incontinence in men

C. Chapple, A. Mangera, 2010 .

European Association of Urology Position Statement on the Role of the Urologist in the Management of Male Hypogonadism and Testosterone Therapy.

A. Salonia, F. Debruyne, P. Verze, 2017, European urology.

Old words revisited—the importance of standardisation

C. Chapple, 2009, Neurourology and urodynamics.

Pasteurella multocida wound infections--a commonly unrecognized problem in the casualty department.

C. Chapple, A. Fraser, 1986, Injury.

Use of endourologic stents in management of benign prostatic hyperplasia

C. Chapple, E. Milroy, D. Richards, 1991 .

Management of hyperparathyroidism in pregnancy

C. Chapple, E. Milroy, J. Sanderson, 1989 .

Muscarinic‐3‐receptor positive allosteric modulator ASP8302 in patients with underactive bladder. A randomized controlled trial

P. Abrams, G. V. van Koeveringe, M. Oelke, 2022, Neurourology and urodynamics.

Underactive Bladder Versus Bladder Outlet Obstruction: Don't Get Tricked!

N. Osman, C. Chapple, 2022, European urology focus.

Comparison of candidate scaffolds for tissue engineering for stress urinary incontinence and pelvic organ prolapse repair

Altaf Mangera, Sheila MacNeil, S. MacNeil, 2013, BJU international.

What was hot at the ICS meeting 2015

B. Couri, N. Osman, C. Chapple, 2016, Neurourology and Urodynamics.

Medical students' exposure to urology in European schools: the European Association of Urology proposals for a convergence programme.

M. Wirth, P. Ekman, U. Jonas, 2010, European urology.

Potential therapeutic targets for treatment of the overactive bladder

R. Chess-Williams, C. Chapple, D. Sellers, 2001, World Journal of Urology.

Stress incontinence due to pelvic floor muscle involvement in limb-girdle muscular dystrophy.

T. Christmas, C. Chapple, P. Dixon, 1990, British journal of urology.

The in vivo response to implantable engineered repair materials designed for pelvic floor reconstruction

S. MacNeil, J. Deprest, G. Callewaert, 2015 .

Response of scaffold materials designed for treatment of stress urinary incontinence (SUI) and pelvic organ prolapse (POP) to distension

S. MacNeil, C. Chapple, S. Roman, 2015 .

Adverse Events with Botox and Dysport for refractory overactive bladder: A systematic review

P. Dasgupta, Muhammad S. Khan, C. Chapple, 2015 .

Clinically Meaningful Improvements in Urinary Incontinence Following Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study

D. Ridder, V. Nitti, C. Chapple, 2015 .

Home based therapeutic application of non-invasive posterior tibial nerve stimulation in the treatment of overactive bladder symptoms: a pilot clinical trial

A. Barker, N. Osman, C. Chapple, 2015 .

Structural and ultrastructural changes in ileal neobladder mucosa: a 7‐year follow up

C. Chapple, 1998 .

Diagnosis and treatment of lower urinary tract symptoms suggestive of overactive bladder and bladder outlet obstruction among men in general practice in the UK

C. Chapple, S. Morant, G. Bloomfield, 2008, International journal of clinical practice.

Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.

M. Oelke, C. Chapple, M. Drake, 2015, European urology.

Moving towards a comprehensive assessment of lower urinary tract symptoms (LUTS)

C. Thompson, K. Coyne, A. Barsdorf, 2012, Neurourology and urodynamics.

The importance of accurate assessment and conservative management of the open bladder neck in patients with post-pelvic fracture membranous urethral distraction defects.

D. Rosario, C. Chapple, S. Macdiarmid, 1995, British journal of urology.

Comparison of Doxazosin With or Without Tolterodine in Men with Symptomatic Bladder Outlet Obstruction and an Overactive Bladder

C. Chapple, 2006 .

Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder

V. Nitti, J. Wyndaele, S. Herschorn, 2014, World Journal of Urology.

Medical Aspects of the Treatment of LUTS/BPH: Antimuscarinic and β3-Agonists

C. Chapple, C. Hillary, 2018 .

Oxybutynin and the overactive bladder

C. Chapple, K. Andersson, 2001, World Journal of Urology.

Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial.

S. Serni, S. Kaplan, K. McVary, 2019, European urology focus.

Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms.

W. D. de Groat, M. Chancellor, C. Gratzke, 2013, European urology.

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)

S. Herschorn, C. Chapple, M. Drake, 2017, International journal of clinical practice.

Pharmacokinetic profile of tamsulosin OCAS

E. Chartier-Kastler, C. Chapple, 2006 .

Bonney's blue cystitis: a warning.

T. Christmas, C. Chapple, E. Milroy, 1989, British journal of urology.

Assessment of BPH/BOO

N. Osman, C. Chapple, A. Mangera, 2014, Indian journal of urology : IJU : journal of the Urological Society of India.

Transurethral needle ablation (TUNA). A critical review of radiofrequency thermal therapy in the management of benign prostatic hyperplasia.

H. Woo, M. Issa, C. Chapple, 1999, European Urology.

[European Association of Urology. Position statement on screening for prostate cancer].

M. Wirth, W. Artibani, C. Chapple, 2010, Actas urologicas espanolas.

The role of alpha1D-adrenoceptors in prostatic contraction examined using protection studies.

R. Chess-Williams, C. Chapple, M. Wyllie, 2002, Autonomic & autacoid pharmacology.

Systematic review of therapy for men with overactive bladder.

C. Chapple, 2011, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Future Directions in Evaluating Nocturia and Its Impact in Patients with LUTS/BPH

R. Berges, E. Chartier-Kastler, H. Stoevelaar, 2006 .

The Pathophysiology of Overactive Bladder

A. Wein, C. Chapple, 2012 .

487: Darifenacin is Well Tolerated and Provides Significant Improvement in the Symptoms of Overactive Bladder: A Pooled Analysis of Phase III Studies

C. Chapple, 2004 .

527: Muscarinic Receptor Function in the Idiopathic Overactive Bladder

R. Chess-Williams, C. Chapple, L. Stevens, 2004 .

A Systematic Review of Surgical interventions for the Treatment of Bladder Pain Syndrome/Interstitial Cystitis.

F. Esperto, N. Osman, C. Chapple, 2020, European urology focus.

The role of M2 muscarinic receptor subtypes mediating contraction of the circular and longitudinal smooth muscle of the pig proximal urethra.

R. Chess-Williams, Ken‐ichiro Yoshida, C. Chapple, 2002, Journal of Urology.

Neurokinin a mediated potentiation of purinergic contraction in the bladder dome of the pig

C. Chapple, R. Williams, L. Templeman, 2003 .

Reply from Authors re: Delphine Behr-Roussel, François A. Giuliano. Sensory Effects of Antimuscarinics: Still a Matter of Debate. Eur Urol 2010;58:29–30

R. Chess-Williams, D. Grundy, C. Chapple, 2010 .

Enhanced adenosine triphosphate release from the urothelium of patients with painful bladder syndrome: a possible pathophysiological explanation.

R. Chess-Williams, A. Surprenant, C. Chapple, 2007, The Journal of urology.

The role of β3‐adrenoceptors in mediating relaxation of porcine detrusor muscle

R. Chess-Williams, Ken‐ichiro Yoshida, C. Chapple, 2002 .

DEPRESSED INHIBITION OF DETRUSOR CONTRACTIONS BY THE UROTHELIUM IN THE HUMAN NEUROGENIC OVERACTIVE BLADDER

C. Chapple, 2003 .

The role of beta(3)-adrenoceptors in mediating relaxation of porcine detrusor muscle.

R. Chess-Williams, Ken‐ichiro Yoshida, C. Chapple, 2002, British journal of pharmacology.

Identification of beta-adrenoceptor subtypes in lower urinary tract of the female pig.

R. Chess-Williams, Ken‐ichiro Yoshida, C. Chapple, 2002, The Journal of urology.

Role of β‐adrenoceptor subtypes in mediating relaxation of the pig bladder trigonal muscle in vitro

R. Chess-Williams, Ken‐ichiro Yoshida, C. Chapple, 2003, Neurourology and urodynamics.

774 DOSE-RANGING STUDY OF ONCE-DAILY MIRABEGRON (YM178), A NOVEL SELECTIVE β3-ADRENOCEPTOR AGONIST, IN PATIENTS WITH OVERACTIVE BLADDER (OAB)

J. Wyndaele, P. Radziszewski, C. Chapple, 2010 .

Tadalafil 5 mg Alone or in Combination with Tamsulosin 0.4 mg for the Management of Men with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Prospective Observational Trial

S. Serni, S. Kaplan, K. McVary, 2019, Journal of clinical medicine.

The Development of the Oral Controlled Absorption System (OCAS®): A New Improved Formulation of Tamsulosin

C. Chapple, 2005 .

Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): Efficacy and Tolerability in a Phase 2b Dose-Response Study

C. Chapple, C. Schulman, M. Reis, 2005 .

C. Chapple, R. Scarpa, B. Gattegno, 2005 .

Are There Pharmacotherapeutic Options for Underactive Bladder?

N. Osman, C. Chapple, 2018, European urology focus.

Are Metallic Endourological Stents an Alternative to Prostatectomy in the Management of Benign Prostatic Hyperplasia

C. Chapple, 1992 .

Outcomes of combination therapy with daily tadalafil 5 mg plus tamsulosin 0.4 mg to treat lower urinary tract symptoms and erectile dysfunction in men with or without metabolic syndrome

S. Serni, S. Kaplan, K. McVary, 2022, Minerva Urology and Nephrology.

Diagnostic Tests for Female Bladder Outlet Obstruction: A Systematic Review from the European Association of Urology Non-neurogenic Female LUTS Guidelines Panel.

M. Lapitan, Yuhong Yuan, R. Campi, 2021, European urology focus.

Corrigendum to “The Effects of Antimuscarinic Treatments in Overactive Bladder: A Systematic Review and Meta-Analysis” [Eur Urol 2005;48:5–26]

Z. Gabriel, C. Chapple, V. Khullar, 2005 .

Diagnosis and treatment of overactive bladder.

N. Osman, C. Chapple, A. Mangera, 2011, Female pelvic medicine & reconstructive surgery.

Low Incidence of Clean Intermittent Catheterisation With OnabotulinumtoxinA in Diverse Age Groups of Overactive Bladder Patients With Corresponding Improvements in Urinary Symptoms, Treatment Response, and Quality of Life

R. Dmochowski, V. Nitti, C. Chapple, 2017 .

Laparoscopic colposuspension - a new procedure

C. Chapple, J. Osborne, 1993 .

Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

C. Roehrborn, D. Cox, M. Oelke, 2014, The Journal of urology.

Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia

C. Chapple, 2010, Current opinion in urology.

Epidemiology of overactive bladder

N. Osman, C. Chapple, 2013 .

The Diagnosis of Urinary Incontinence: Urodynamics, More or Less?

C. Chapple, 2002 .

The investigation of female stress incontinence

K. Kreder, C. Chapple, D. Smith, 1994, International Urogynecology Journal.

Are biomechanical properties predictive of the success of prostheses used in stress urinary incontinence and pelvic organ prolapse? A systematic review

S. MacNeil, C. Chapple, A. Mangera, 2012, Neurourology and urodynamics.

Acute In Vivo Response to an Alternative Implant for Urogynecology

S. MacNeil, J. Deprest, M. Albersen, 2014, BioMed research international.

Indications for Treatment

N. Osman, C. Chapple, C. Hillary, 2017 .

ICONS II: Identifying Continence OptioNs after Stroke randomised controlled trial

L. Thomas, C. Sutton, C. Watkins, 2018 .

FESOTERODINE IN NON-NEUROGENIC VOIDING DYSFUNCTION RESULTS ON EFFICACY AND SAFETY IN A PHASE 3 TRIAL

A. Tubaro, C. Chapple, R. Millard, 2006 .

Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED

S. Serni, K. McVary, L. Vignozzi, 2020, Current Urology Reports.

Re: Rosario DJ, Woo HH, Chapple CR. 2008. Definition of normality of pressure‐flow parameters based on observations in asymptomatic men. Neurourol and Urodynam 27:388–394

D. Rosario, C. Chapple, 2009 .

European Association of Urology position statement on screening for prostate cancer.

M. Wirth, W. Artibani, C. Chapple, 2009, European urology.

Double‐blind multicenter study comparing alprostadil alpha‐cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction

C. Chapple, 1998 .

Improvement in Health-Related Quality of Life Following Treatment With OnabotulinumtoxinA in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity

M. Chancellor, C. Chapple, W. Lam, 2011 .

Prevalence and predictors of overactive bladder in nonpregnant nulliparous women below 65 years of age

D. Robinson, C. Chapple, I. Milsom, 2017, International Urogynecology Journal.

Nocturia: risk factors and associated comorbidities; findings from the EpiLUTS study

K. Coyne, C. Chapple, I. Milsom, 2015, International journal of clinical practice.

ROLE OF SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN VOIDING DYSFUNCTION

T. Christmas, A. Lees, C. Chapple, 1988, The Lancet.

Results of radical prostatectomy in men with locally advanced prostate cancer: multi‐institutional pooled analysis

C. Chapple, 1998 .

Clinical and Patient-reported Outcome Measures in Men Referred for Consideration of Surgery to Treat Lower Urinary Tract Symptoms: Baseline Results and Diagnostic Findings of the Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM).

S. Noble, J. McGrath, J. Lane, 2019, European urology focus.

What's new in … Neurology: incontinence

C. Chapple, Vivekanandan Kumar, 2004 .

Perforation of continent urinary reservoirs

C. Chapple, 1998 .

An uncommon complication of circumcision.

F. Hamdy, C. Chapple, D. Smith, 1994, British journal of urology.

Reply: Unravelling Fowler's syndrome-current pathophysiological concepts.

N. Osman, C. Chapple, 2014, Nature reviews. Urology.

Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.

A. Tubaro, C. Chapple, M. Brodsky, 2007, European urology.

Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo‐ and tolterodine‐controlled phase 2 dose‐finding study

D. Ridder, D. de Ridder, C. Chapple, 2004, BJU international.

Efficacy of trospium chloride in patients with detrusor instability: a placebo‐controlled, randomized, double‐blind, multicentre clinical trial

W. Lehmacher, L. Cardozo, C. Chapple, 2000, BJU international.

Bladder pain syndrome/interstitial cystitis: a sense of urgency

L. Cardozo, P. Hanno, C. Chapple, 2009, World Journal of Urology.

Excision of a symptomatic unusual duplicated urethra in an adult male

N. Osman, C. Chapple, C. Hillary, 2017 .

A simple technique for the intra-operative placement of a suprapubic catheter.

H. Woo, D. Rosario, C. Chapple, 1996, British journal of urology.

Tissue engineering in urethral reconstruction

C. Chapple, A. Mangera, 2010, F1000 medicine reports.

Urodynamics Made Easy

C. Chapple, S. Macdiarmid, 1990 .

Urological diagnosis – history and investigations

J. Catto, C. Chapple, 2002 .

The black thyroid: an unusual finding during neck exploration.

T. Christmas, C. Chapple, E. Milroy, 1989, Postgraduate medical journal.

Theblack thyroid: anunusual finding during neckexploration

T. Christmas, C. Chapple, J. Noble, 1989 .

Conservative management of urinary incontinence following robot-assisted radical prostatectomy.

F. Esperto, R. Papalia, F. Porpiglia, 2020, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review

C. Roehrborn, P. Abrams, C. Roehrborn, 2011, International journal of clinical practice.

A pragmatic approach to the primary care management of men with lower urinary tract symptoms

C. Chapple, A. Patel, 2007, International journal of clinical practice.

Buccal mucosal urethroplasty: is it the new gold standard?

C. Chapple, S Bhargava, C R Chapple, 2004, BJU international.

Comparative study of selective alpha 1-adrenoceptor blockade versus surgery in the treatment of prostatic obstruction.

C. Chapple, E. Milroy, J. Noble, 1993, British journal of urology.

Updated Systematic Review and Meta-analysis of the Comparative Data on Colposuspensions, Pubovaginal Slings, and Midurethral Tapes in the Surgical Treatment of Female Stress Urinary Incontinence.

M. Creta, D. Waltregny, G. Novara, 2017, European urology.

Assessing patients’ descriptions of lower urinary tract symptoms (LUTS) and perspectives on treatment outcomes: results of qualitative research

K. Coyne, T. Symonds, C. Chapple, 2010, International journal of clinical practice.

An unusual renal mass: ?Wegener's granulomatosis.

C. Chapple, C. Milroy, D. Smith, 1993, British journal of urology.

Long-term follow-up after tissue-engineered buccal mucosa urethroplasty.

S. MacNeil, N. Osman, C. Chapple, 2014, European urology.

Gastric adenocarcinoma associated with adenomyoma of the stomach.

J. Newman, C. Chapple, S. Muller, 1988, Postgraduate medical journal.

Alpha-adrenergic blocking drugs in bladder outflow obstruction: what potential has alpha 1-adrenoceptor selectivity?

C. Chapple, 1995, British journal of urology.

New medical developments in the management of LUTS in adult men

T. Tammela, S. Kaplan, P. Teillac, 2006 .

A Systematic Review and Meta-analysis of Adjuncts to Minimally Invasive Treatment of Urethral Stricture in Men.

K. Pang, N. Osman, D. Hind, 2021, European urology.

Outcomes of combination therapy with daily Tadalafil 5mg plus Tamsulosin 0.4mg to treat lower urinary tract symptoms and erectile dysfunction in men with or without metabolic syndrome.

S. Serni, S. Kaplan, K. McVary, 2020, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

Comparison of fesoterodine and tolterodine in patients with overactive bladder

K. Jünemann, C. Chapple, M. Brodsky, 2008, BJU international.

Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.

F. Montorsi, P. Albers, M. Roobol, 2019, European urology.

508 New antimuscarinic agent, solifenacin succinate, reduces urgency episodes in overactive bladder: An analysis of over 3000 patients

U. Jonas, M. Chancellor, C. Chapple, 2004 .

LOW INCIDENCE OF CLEAN INTERMITTENT CATHETERIZATION WITH ONABOTULINUMTOXINA IN DIVERSE AGE GROUPS OF OVERACTIVE BLADDER PATIENTS WITH SUBSTANTIAL IMPROVEMENTS IN TREATMENT RESPONSE: PD39‐01

R. Dmochowski, V. Nitti, C. Chapple, 2017 .

512 Darifenacin is effective in improving the major symptoms of overactive bladder: A pooled analysis of phase III studies

C. Chapple, 2004 .

Efficacy and Safety of Eliapixant in Overactive Bladder: The 12-Week, Randomised, Placebo-controlled Phase 2a OVADER Study.

C. Chapple, F. Cruz, S. Klein, 2023, European urology focus.

Neuromodulation and Surgical Approaches

A. Wein, C. Chapple, 2012 .

Introduction and Conclusions

C. Chapple, 2001, European Urology.

Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis.

R. Dmochowski, P. Abrams, P. van Kerrebroeck, 2014, European urology.

A Study of the Validity of Voiding Pressure — Flow Plot Interpretation in Clinical Urodynamics

J. G. Malone-Lee, C. R. Chapple, C. Chapple, 1988 .

Medical Expulsive Therapy for Ureterolithiasis: The EAU Recommendations in 2016.

T. Knoll, C. Türk, A. Skolarikos, 2017, European urology.

Management of urinary incontinence in men

N. Mangır, C. Chapple, 2020 .

Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies

M. Oelke, V. Nitti, A. Tubaro, 2017, Therapeutic advances in urology.

Re: Age and Bladder Outlet Obstruction are Independently Associated with Detrusor Overactivity in Patients with Benign Prostatic Hyperplasia

C. Chapple, 2009 .

What was “hot” at the ICS annual meeting San Francisco 2009

C. Chapple, R. Cartwright, Hashim Hashim, 2010, Neurourology and urodynamics.

Application of Tissue Engineering to Pelvic Organ Prolapse and Stress Urinary Incontinence

S. MacNeil, N. Osman, C. Chapple, 2015, Lower urinary tract symptoms.

Clinical stage, prostate specific antigen and gleason grade to predict extracapsular disease or nodal metastasis in men with newly diagnosed, previously untreated prostate cancer

C. Chapple, 1998 .

The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.

Z. Gabriel, C. Chapple, V. Khullar, 2008, European urology.

Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex.

L. Phillips, E. Chartier-Kastler, A. Tubaro, 2020, European urology focus.

Factors involved in the success of antimuscarinic treatment

P. Abrams, A. Wein, C. Chapple, 1999, BJU international.

C. Nardo, P. Radziszewski, C. Chapple, 2013, European urology.

OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity

R. Dmochowski, C. Chapple, W. Lam, 2011, Neurourology and urodynamics.